## Scott B. Patten

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2332858/publications.pdf

Version: 2024-02-01

804 papers

117,829 citations

101 h-index 320 g-index

829 all docs

829 docs citations

829 times ranked 131252 citing authors

#	Article	IF	CITATIONS
1	Association Between Excess Sleep Duration and Risk of Stroke: A Population-Based Study. Canadian Journal of Neurological Sciences, 2023, 50, 17-22.	0.5	3
2	The impact of the <scp>COVID</scp> â€19 pandemic on eating disorders: A systematic review. International Journal of Eating Disorders, 2023, 56, 5-25.	4.0	127
3	Validating the Mild Behavioral Impairment Checklist in a Cognitive Clinic: Comparisons With the Neuropsychiatric Inventory Questionnaire. Journal of Geriatric Psychiatry and Neurology, 2023, 36, 107-120.	2.3	28
4	Psychological characteristics and childhood adversity of adolescents with atypical anorexia nervosa versus anorexia nervosa. Eating Disorders, 2022, 30, 210-222.	3.0	19
5	Does providing personalized depression risk information lead to increased psychological distress and functional impairment? Results from a mixed-methods randomized controlled trial. Psychological Medicine, 2022, 52, 2071-2079.	4.5	8
6	Comparison of different scoring methods based on latent variable models of the PHQ-9: an individual participant data meta-analysis. Psychological Medicine, 2022, 52, 3472-3483.	4.5	9
7	Increasing Rates of Youth and Adolescent Suicide in Canadian Women. Canadian Journal of Psychiatry, 2022, 67, 67-69.	1.9	1
8	Considering a risk profile based on emergency department utilization in young people with eating disorders: Implications for early detection. International Journal of Eating Disorders, 2022, 55, 1219-1228.	4.0	4
9	"Teachers Often See the Red Flags First― Perceptions of School Staff Regarding Their Roles in Supporting Students with Mental Health Concerns. School Mental Health, 2022, 14, 402-415.	2.1	21
10	Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders. Psychosomatic Medicine, 2022, 84, 10-19.	2.0	15
11	External validation of a shortened screening tool using individual participant data meta-analysis: A case study of the Patient Health Questionnaire-Dep-4. Methods, 2022, 204, 300-311.	3.8	3
12	Mental health before and during the pandemic in people with systemic sclerosis. Lancet Rheumatology, The, 2022, 4, e82-e85.	3.9	9
13	Experiences of Canadian mental health providers in identifying and responding to online and in-person sexual abuse and exploitation of their child and adolescent clients. Child Abuse and Neglect, 2022, 124, 105448.	2.6	11
14	Vascular risk factors and stroke risk across the life span: A population-representative study of half a million people. International Journal of Stroke, 2022, 17, 1021-1029.	5.9	2
15	Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry,the, 2022, 9, 137-150.	7.4	1,487
16	Productivity loss among people with early multiple sclerosis: A Canadian study. Multiple Sclerosis Journal, 2022, 28, 1414-1423.	3.0	12
17	Validity and reliability of global ratings of satisfaction with epilepsy surgery. Epilepsia, 2022, 63, 777-788.	5.1	3
18	Confidence, Training and Challenges for Canadian Child Advocacy Center Staff When Working with Cases of Online and In-person Child Sexual Exploitation. Journal of Child Sexual Abuse, 2022, 31, 297-315.	1.3	3

#	Article	IF	Citations
19	Psychiatric Outcomes in ICU Patients With Family Visitation. Chest, 2022, 162, 578-587.	0.8	5
20	10-Year Trends in Healthcare Spending among Patients with Schizophrenia in Alberta, Canada. Canadian Journal of Psychiatry, 2022, , 070674372210828.	1.9	2
21	Measuring Stigma Towards People with Opioid Use Problems: Exploratory and Confirmatory Factor Analysis of the Opening Minds Provider Attitudes Towards Opioid-Use Scale (OM-PATOS). International Journal of Mental Health and Addiction, 2022, , 1-12.	7.4	1
22	Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review. Journal of Cannabis Research, 2022, 4, 11.	3.2	6
23	Understanding the impact of COVID-19 isolation measures on individuals with mood disorders in mental health clinics. Journal of Affective Disorders Reports, 2022, 8, 100348.	1.7	1
24	Association between antiseizure medications and quality of life in epilepsy: A mediation analysis. Epilepsia, 2022, 63, 440-450.	5.1	17
25	Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 874724.	2.4	4
26	Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease. General Hospital Psychiatry, 2022, 77, 21-28.	2.4	5
27	Protocol for READY2Exit: a patient-oriented, mixed methods study examining transition readiness in adolescents with co-occurring physical and mental health conditions. Journal of Transition Medicine, 2022, 4, .	0.5	4
28	Measuring the Influence of Curricular Content and Personal Stories on Substance Use Stigma. Journal of Nursing Education, 2022, 61, 264-267.	0.9	2
29	Alternative scoring of the Patient Health Questionnaire-9 in neurological populations: an approach based on a predictive algorithm deriving from individual item scores. General Hospital Psychiatry, 2022, 77, 37-39.	2.4	1
30	Effect of mood and anxiety disorders on health care utilization in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1411-1420.	3.0	6
31	Rationale and Methodology of the 2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): A 16-year Follow-up Survey: Raison D'être Et Méthodologie De L'enquê De Suivi Sur La Santé Mentale Des Membres Des Forces Armées Canadiennes Et Des Anciens Combattants, 2018 (ESSMFACM), Canadian Iournal of Psychiatry, 2021, 66, 942-950.	te 1.9	12
32	Prevalence of Mental III-Health in a Cohort of First Responders Attending the Fort McMurray Fire. Canadian Journal of Psychiatry, 2021, 66, 719-725.	1.9	7
33	A Viewpoint: Validation of Self-Reported Anxiety Screening Scales in Perinatal Populations– Outstanding Issues in the Validation Research Agenda. Canadian Journal of Nursing Research, 2021, 53, 187-190.	1.5	O
34	Our Digital Moment: Innovations and Opportunities in Digital Mental Health Care. Canadian Journal of Psychiatry, 2021, 66, 5-8.	1.9	43
35	Assessment of anxiety during pregnancy: are existing multiple anxiety scales suitable and comparable in measuring anxiety during pregnancy?. Journal of Psychosomatic Obstetrics and Gynaecology, 2021, 42, 140-146.	2.1	8
36	Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 58-64.	1.9	12

#	Article	IF	CITATIONS
37	Cannabis and non-psychotic mental disorders. Current Opinion in Psychology, 2021, 38, 61-66.	4.9	4
38	Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Populationâ€Based Study. Arthritis Care and Research, 2021, 73, 90-99.	3.4	6
39	<i>P</i> Values and Confidence Intervals. Canadian Journal of Psychiatry, 2021, 66, 421-422.	1.9	O
40	Depression prevalence based on the Edinburgh Postnatal Depression Scale compared to Structured Clinical Interview for DSM DIsorders classification: Systematic review and individual participant data metaâ€analysis. International Journal of Methods in Psychiatric Research, 2021, 30, e1860.	2.1	30
41	Emerging Patterns of E-Cigarette Use in the General Population. Canadian Journal of Psychiatry, 2021, 66, 503-505.	1.9	7
42	Risk of Depression in Patients With Psoriatic Disease: A Systematic Review and Meta-Analysis. Journal of Cutaneous Medicine and Surgery, 2021, 25, 257-270.	1.2	15
43	How a shared humanity model can improve provider well-being and client care: An evaluation of Fraser Health's Trauma and Resiliency Informed Practice (TRIP) training program. Healthcare Management Forum, 2021, 34, 87-92.	1.4	5
44	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. Journal of Psychosomatic Research, 2021, 140, 110314.	2.6	9
45	Primary care electronic medical records can be used to predict risk and identify potentially modifiable factors for early and late death in adult onset epilepsy. Epilepsia, 2021, 62, 51-60.	5.1	9
46	Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three Individual Participant Data Meta-Analyses. Psychotherapy and Psychosomatics, 2021, 90, 28-40.	8.8	20
47	The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. Inflammatory Bowel Diseases, 2021, 27, 1285-1293.	1.9	64
48	Course and Predictors of Major Depressive Disorder in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey: Cours et Prédicteurs du Trouble de Dépression Majeure Dans l'Enquête de Suivi Sur la Sant© Mentale Auprès Des Membres des Forces Armées Canadiennes et des ex-Militaires. Canadian Journal of Psychiatry, 2021, 66, 971-981.	1.9	10
49	Screening for depression in children and adolescents: a protocol for a systematic review update. Systematic Reviews, 2021, 10, 24.	5.3	11
50	Capacity, confidence and training of Canadian educators and school staff to recognize and respond to sexual abuse and internet exploitation of their students. Child Abuse and Neglect, 2021, 112, 104898.	2.6	11
51	Poor Mental Health during the COVD-19 Pandemic: Effect Modification by Age. Canadian Journal of Psychiatry, 2021, 66, 827-829.	1.9	14
52	Birth outcomes, pregnancy complications, and postpartum mental health after the 2013 Calgary flood: A difference in difference analysis. PLoS ONE, 2021, 16, e0246670.	2.5	20
53	Outdoor Air Pollution and Depression in Canada: A Population-Based Cross-Sectional Study from 2011 to 2016. International Journal of Environmental Research and Public Health, 2021, 18, 2450.	2.6	12
54	Patterns of Attrition in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS). Canadian Journal of Psychiatry, 2021, 66, 996-998.	1.9	13

#	Article	IF	CITATIONS
55	Population Mental Health and COVID-19: Why Do We Know So Little?. Canadian Journal of Psychiatry, 2021, 66, 070674372110105.	1.9	7
56	Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents. JAMA Network Open, 2021, 4, e216614.	5.9	23
57	Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study. CMAJ Open, 2021, 9, E510-E521.	2.4	10
58	Childhood care and abuse in firefighters assessed for mental ill-health following the Fort McMurray fire of May 2016 Journal of Affective Disorders Reports, 2021, 4, 100090.	1.7	3
59	Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ, The, 2021, 373, n972.	6.0	77
60	The WHODAS-2 and Community Psychiatry. Canadian Journal of Psychiatry, 2021, 66, 1094-1095.	1.9	1
61	Impairment in health-related quality of life among community-dwelling stroke survivors. Canadian Journal of Neurological Sciences, 2021, , 1-23.	0.5	0
62	The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2021, 145, 110479.	2.6	11
63	An environmental scan of visitation policies in Canadian intensive care units during the first wave of the COVID-19 pandemic. Canadian Journal of Anaesthesia, 2021, 68, 1474-1484.	1.6	31
64	The Burden of Mental Illness and Evidence-informed Mental Health Policy Development. Canadian Journal of Psychiatry, 2021, , 070674372110212.	1.9	2
65	Effects of a multi-faceted education and support programme on anxiety symptoms among people with systemic sclerosis and anxiety during COVID-19 (SPIN-CHAT): a two-arm parallel, partially nested, randomised, controlled trial. Lancet Rheumatology, The, 2021, 3, e427-e437.	3.9	24
66	The impact of providing personalized depression risk information on selfâ€help and helpâ€seeking behaviors: Results from a mixed methods randomized controlled trial. Depression and Anxiety, 2021, 38, 917-924.	4.1	3
67	Predicting postoperative epilepsy surgery satisfaction in adults using the 19â€item Epilepsy Surgery Satisfaction Questionnaire and machine learning. Epilepsia, 2021, 62, 2103-2112.	5.1	6
68	Quality of Life in Epilepsy: Same questions, but different meaning to different people. Epilepsia, 2021, 62, 2094-2102.	5.1	7
69	Mental Health Interventions to Improve Psychological Outcomes in Informal Caregivers of Critically Ill Patients: A Systematic Review and Meta-Analysis*. Critical Care Medicine, 2021, 49, 1414-1426.	0.9	15
70	Self-help behaviors partially mediate the relationship between personalized depression risk disclosure and psychological distress: A mediation analysis using data from a randomized controlled trial. Journal of Psychiatric Research, 2021, 140, 7-14.	3.1	0
71	Association Between Physical Activity and Mortality Among Community-Dwelling Stroke Survivors. Neurology, 2021, 97, .	1.1	6
72	Association Between Excess Leisure Sedentary Time and Risk of Stroke in Young Individuals. Stroke, 2021, 52, 3562-3568.	2.0	12

#	Article	IF	Citations
73	Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. PLoS ONE, 2021, 16, e0249809.	2.5	6
74	The Prevalence of Cannabis Use Disorder Comorbidity in Individuals With Bipolar Disorder: A Systematic Review and Meta-Analysis. Canadian Journal of Addiction, 2021, 12, 22-38.	0.4	3
75	Impact of restricted visitation policies in hospitals on patients, family members and healthcare providers during the COVID-19 pandemic: a scoping review protocol. BMJ Open, 2021, 11, e048227.	1.9	6
76	Can the adverse childhood experiences (ACEs) checklist be utilized to predict emergency department visits among children and adolescents?. BMC Medical Research Methodology, 2021, 21, 195.	3.1	3
77	Self-Reported Lifetime History of Eating Disorders and Mortality in the General Population: A Canadian Population Survey with Record Linkage. Nutrients, 2021, 13, 3333.	4.1	4
78	Data-driven methods distort optimal cutoffs and accuracy estimates of depression screening tools: a simulation study using individual participant data. Journal of Clinical Epidemiology, 2021, 137, 137-147.	5.0	9
79	Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis. ACR Open Rheumatology, 2021, 3, 889-896.	2.1	3
80	Restricted visitation policies in acute care settings during the COVID-19 pandemic: a scoping review. Critical Care, 2021, 25, 347.	5.8	45
81	Healthcare utilization and mortality outcomes in patients with pre-existing psychiatric disorders after intensive care unit discharge: A population-based retrospective cohort study. Journal of Critical Care, 2021, 66, 67-74.	2.2	4
82	Shortening the Edinburgh postnatal depression scale using optimal test assembly methods: Development of the EPDSâ€Depâ€5. Acta Psychiatrica Scandinavica, 2021, 143, 348-362.	4.5	5
83	Understanding the impact of the COVID-19 pandemic on well-being and virtual care for people living with dementia and care partners living in the community. Dementia, 2021, 20, 2007-2023.	2.0	56
84	The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design. BMC Neurology, 2021, 21, 418.	1.8	5
85	26 Supporting the Transition to Postsecondary for Students with Mental Health Conditions: A Scoping Review. Paediatrics and Child Health, 2021, 26, e19-e21.	0.6	1
86	Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2021, 398, 1593-1618.	13.7	92
87	Vaping and Mental Health. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2021, 30, 3-5.	0.6	5
88	Data Harmonization and Data Pooling from Cohort Studies: A Practical Approach for Data Management. International Journal of Population Data Science, 2021, 6, 1680.	0.1	14
89	Users' perceptions about receiving personalized depression risk information: findings from a qualitative study. BMC Psychiatry, 2021, 21, 581.	2.6	1
90	The Prevalence of Impulse Control Disorders and Behavioral Addictions in Eating Disorders: A Systematic Review and Meta-Analysis. Frontiers in Psychiatry, 2021, 12, 724034.	2.6	4

#	Article	IF	CITATIONS
91	The effect of interventions targeting gut microbiota on depressive symptoms: a systematic review and meta-analysis. CMAJ Open, 2021, 9, E1195-E1204.	2.4	21
92	The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis. Journal of Eating Disorders, 2021, 9, 161.	2.7	12
93	Recent Trends in the Prescribing of ADHD Medications in Canadian Primary Care. Journal of Attention Disorders, 2020, 24, 301-308.	2.6	9
94	Changing trends in coding for depression among the UK IBD population: reply from authors. Gut, 2020, 69, 607.2-607.	12.1	1
95	"If it helps someone, then I want to do it― Perspectives of persons living with dementia on research registry participation. Dementia, 2020, 19, 2525-2541.	2.0	5
96	Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 1130-1139.	3.4	63
97	Subtyping psychological distress in the population: a semi-parametric network approach. Epidemiology and Psychiatric Sciences, 2020, 29, e36.	3.9	1
98	Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors. Gut, 2020, 69, 611-612.	12.1	2
99	Electronic cigarette use and mental health: A Canadian population-based study. Journal of Affective Disorders, 2020, 260, 646-652.	4.1	39
100	Seasonal variation in specific depressive symptoms: A population based study. Journal of Affective Disorders, 2020, 261, 153-159.	4.1	13
101	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. Psychotherapy and Psychosomatics, 2020, 89, 25-37.	8.8	67
102	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. Psychological Medicine, 2020, 50, 1368-1380.	4.5	175
103	Mental Health among Canadian Postsecondary Students: A Mental Health Crisis?. Canadian Journal of Psychiatry, 2020, 65, 30-35.	1.9	23
104	Does the neuropsychiatric inventory predict progression from mild cognitive impairment to dementia? A systematic review and meta-analysis. Ageing Research Reviews, 2020, 58, 101004.	10.9	17
105	On the need for epidemiology in psychiatric sciences. Epidemiology and Psychiatric Sciences, 2020, 29, e1.	3.9	9
106	Predicting death by suicide using administrative health care system data: Can recurrent neural network, one-dimensional convolutional neural network, and gradient boosted trees models improve prediction performance?. Journal of Affective Disorders, 2020, 264, 107-114.	4.1	16
107	Synthesis and biological assessment of a ruthenium(II) cyclopentadienyl complex in breast cancer cells and on the development of zebrafish embryos. European Journal of Medicinal Chemistry, 2020, 188, 112030.	5 <b>.</b> 5	31
108	Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale – Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. Journal of Psychosomatic Research, 2020, 129, 109892.	2.6	33

#	Article	IF	CITATIONS
109	Social phobia in immune-mediated inflammatory diseases. Journal of Psychosomatic Research, 2020, 128, 109890.	2.6	6
110	Antidepressant Prescriptions, Including Tricyclics, Continue to Increase in Canadian Children. Journal of Child and Adolescent Psychopharmacology, 2020, 30, 381-388.	1.3	4
111	A Great Catch for Investigating Inborn Errors of Metabolism—Insights Obtained from Zebrafish. Biomolecules, 2020, 10, 1352.	4.0	8
112	Depression prevalence using the HADS-D compared to SCID major depression classification: An individual participant data meta-analysis. Journal of Psychosomatic Research, 2020, 139, 110256.	2.6	19
113	Mental disorders and subsequent suicide events in a representative community population. Journal of Affective Disorders, 2020, 277, 456-462.	4.1	6
114	Development and validation of the Epilepsy Surgery Satisfaction Questionnaire (ESSQâ€19). Epilepsia, 2020, 61, 2729-2738.	5.1	13
115	Validation of the COVID-19 Fears Questionnaires for Chronic Medical Conditions: A Scleroderma Patient-centered Intervention Network COVID-19 Cohort study. Journal of Psychosomatic Research, 2020, 139, 110271.	2.6	20
116	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1204-1222.	13.7	7,664
117	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1223-1249.	13.7	3,928
118	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
119	16742 Depression as a risk factor for the development of psoriasis. Journal of the American Academy of Dermatology, 2020, 83, AB69.	1.2	1
120	Examining the impacts of the COVID-19 pandemic on the well-being and virtual care of patients with epilepsy. Epilepsy and Behavior, 2020, 113, 107599.	1.7	16
121	Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. BMJ, The, 2020, 371, m4022.	6.0	298
122	The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 27, 1462-1474.	1.9	10
123	Association between delirium in the intensive care unit and subsequent neuropsychiatric disorders. Critical Care, 2020, 24, 476.	5.8	15
124	Current perspectives on co-morbid depression and multiple sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 867-874.	2.8	9
125	Modelling C9orf72-Related Amyotrophic Lateral Sclerosis in Zebrafish. Biomedicines, 2020, 8, 440.	3.2	10
126	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. Journal of Psychosomatic Research, 2020, 139, 110262.	2.6	25

#	Article	IF	CITATIONS
127	Overestimation of Postpartum Depression Prevalence Based on a 5-item Version of the EPDS: Systematic Review and Individual Participant Data Meta-analysis. Canadian Journal of Psychiatry, 2020, 65, 835-844.	1.9	9
128	The association of recreational and non-recreational physical activity with mental health: A Canadian cross-sectional analysis Journal of Affective Disorders Reports, 2020, 1, 100021.	1.7	5
129	Driving Under the Influence of Cannabis in Canada, 2015 to 2018. Canadian Journal of Psychiatry, 2020, 65, 674-675.	1.9	O
130	Mental Health of Communities during the COVID-19 Pandemic. Canadian Journal of Psychiatry, 2020, 65, 681-687.	1.9	157
131	Neighbourhood socioeconomic status modifies the association between anxiety and depression during pregnancy and preterm birth: a Community-based Canadian cohort study. BMJ Open, 2020, 10, e031035.	1.9	14
132	The relationship between depression risk perception and self-help behaviours in high risk Canadians: a cross-sectional study. BMC Public Health, 2020, 20, 876.	2.9	4
133	Validity of the Patient Health Questionnaire-9 in neurologic populations. Neurology: Clinical Practice, 2020, 10, 190-198.	1.6	13
134	Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression. JAMA - Journal of the American Medical Association, 2020, 323, 2290.	7.4	242
135	The Association of Active Living Environments and Mental Health: A Canadian Epidemiological Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 1910.	2.6	7
136	Maternal chronic disease and breastfeeding outcomes: a Canadian population-based study. Journal of Maternal-Fetal and Neonatal Medicine, 2020, , $1\text{-}8$ .	1.5	12
137	Predicting death by suicide following an emergency department visit for parasuicide with administrative health care system data and machine learning. EClinicalMedicine, 2020, 20, 100281.	7.1	25
138	Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. Journal of Clinical Epidemiology, 2020, 122, 115-128.e1.	5.0	113
139	The accuracy of depression risk perception in high risk Canadians. Journal of Affective Disorders, 2020, 265, 410-415.	4.1	7
140	Cannabis Use and Internalizing/Externalizing Symptoms in Youth: A Canadian Population-Based Study. Journal of Adolescent Health, 2020, 67, 26-32.	2.5	7
141	Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases. Epidemiology and Psychiatric Sciences, 2020, 29, e84.	3.9	4
142	Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. Statistical Methods in Medical Research, 2020, 29, 2520-2537.	1.5	366
143	Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Crohn's & Colitis 360, 2020, 2, otz053.	1.1	8
144	Depression as a risk factor for the development of psoriasis: a retrospective cohort study in the <scp>UK</scp> . British Journal of Dermatology, 2020, 183, 776-778.	1.5	7

#	Article	IF	Citations
145	A growing need for youth mental health services in Canada: examining trends in youth mental health from 2011 to 2018. Epidemiology and Psychiatric Sciences, 2020, 29, e115.	3.9	108
146	Smoking Cessation and Improvement in Mental Health Outcomes: Do People Who Quit Smoking by Switching to Electronic Cigarettes Experience Improvement in Mental Health?. Canadian Journal of Psychiatry, 2020, 65, 512-514.	1.9	7
147	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. Journal of Psychosomatic Research, 2020, 135, 110132.	2.6	21
148	Psychosocial profiles and their predictors in epilepsy using patientâ€reported outcomes and machine learning. Epilepsia, 2020, 61, 1201-1210.	5.1	10
149	The Effects of microRNA-515-5p on the Toll-Like Receptor 4 (TLR4)/JNK Signaling Pathway and WNT1-Inducible-Signaling Pathway Protein 1 (WISP-1) Expression in Rheumatoid Arthritis Fibroblast-Like Synovial (RAFLS) Cells Following Treatment with Receptor Activator of Nuclear Factor-kappa-B Ligand (RANKL), Medical Science Monitor, 2020, 26, e920611.	1.1	8
150	Mandatory HIV screening, migration and HIV stigma in Canada: exploring the experiences of sub-Saharan African immigrants living with HIV in western Canada. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2020, 40, 38-46.	1.1	8
151	Sexualized drug use in virtual space: A scoping review of how gay, bisexual and other men who have sex with men interact online. Canadian Journal of Human Sexuality, 2020, 29, 106-126.	1.6	9
152	Mental Disorders and Subsequent Suicide in A Representative Community Population. International Journal of Population Data Science, 2020, 5, .	0.1	0
153	Physical Activity and Mental Health: A Cross-sectional Study of Canadian Youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 2020, 29, 241-252.	0.6	2
154	Child abuse and all-cause mortality in the Canadian population. European Journal of Public Health, 2020, 30, .	0.3	0
155	Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 360-368.	1.9	166
156	Mental health care for university students: a way forward?. Lancet Psychiatry, the, 2019, 6, 885-887.	7.4	111
157	Predicting death by suicide using administrative health care system data: Can feedforward neural network models improve upon logistic regression models?. Journal of Affective Disorders, 2019, 257, 741-747.	4.1	13
158	The Pharmacoepidemiology of Psychotropic Medication Use in Canadian Children from 2012 to 2016. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 740-745.	1.3	17
159	Association of Levels of Specialized Care With Risk of Premature Mortality in Patients With Epilepsy. JAMA Neurology, 2019, 76, 1352.	9.0	40
160	Psychopharmacology of multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 309-315.	1.8	3
161	Risk of adverse perinatal outcomes among women with pharmacologically treated and untreated depression during pregnancy: A retrospective cohort study. Paediatric and Perinatal Epidemiology, 2019, 33, 323-331.	1.7	13
162	Comparison of major depression diagnostic classification probability using the SCID, CIDI, and MINI diagnostic interviews among women in pregnancy or postpartum: An individual participant data metaâ€analysis. International Journal of Methods in Psychiatric Research, 2019, 28, e1803.	2.1	34

#	Article	IF	Citations
163	A randomized controlled trial to examine the impacts of disclosing personalized depression risk information on the outcomes of individuals who are at high risk of developing major depression: a research protocol. BMC Psychiatry, 2019, 19, 285.	2.6	8
164	Validation of a case definition for depression in administrative data against primary chart data as a reference standard. BMC Psychiatry, 2019, 19, 9.	2.6	76
165	Bidirectional association between major depressive disorder and alopecia areata: A population-based study. Journal of the American Academy of Dermatology, 2019, 81, AB26.	1.2	0
166	Vitiligo and major depressive disorder: A bidirectional population-based cohort study. Journal of the American Academy of Dermatology, 2019, 81, AB147.	1.2	0
167	Prediction Tools for Psychiatric Adverse Effects After Levetiracetam Prescription. JAMA Neurology, 2019, 76, 440.	9.0	73
168	Screening for depression in women during pregnancy or the first year postpartum and in the general adult population: a protocol for two systematic reviews to update a guideline of the Canadian Task Force on Preventive Health Care. Systematic Reviews, 2019, 8, 27.	5 <b>.</b> 3	30
169	Resolving the paradox of increased mental health expenditure and stable prevalence. Australian and New Zealand Journal of Psychiatry, 2019, 53, 844-850.	2.3	21
170	Seasonal variation in symptoms of depression: A Canadian population based study. Journal of Affective Disorders, 2019, 255, 142-149.	4.1	29
171	Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. Patient Education and Counseling, 2019, 102, 1722-1729.	2.2	12
172	The 2014 Ontario Child Health Study. Canadian Journal of Psychiatry, 2019, 64, 225-226.	1.9	1
173	The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1674-1680.	1.9	73
174	Assessment of the burden of diseases and injuries attributable to risk factors in Canada from 1990 to 2016: an analysis of the Global Burden of Disease Study. CMAJ Open, 2019, 7, E140-E148.	2.4	29
175	Living with Migraine in Canada – A National Community-Based Study. Canadian Journal of Neurological Sciences, 2019, 46, 216-223.	0.5	6
176	Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ: British Medical Journal, 2019, 365, 11476.	2.3	822
177	Global assessment of migraine severity measure: preliminary evidence of construct validity. BMC Neurology, 2019, 19, 53.	1.8	17
178	Does neighborhood socioeconomic status predict the risk of preterm birth? A community-based Canadian cohort study. BMJ Open, 2019, 9, e025341.	1.9	9
179	Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. BMJ: British Medical Journal, 2019, 364, 194.	2.3	558
180	Could Depression be Preventable? Evidence and Perspectives. , 2019, , 257-263.		0

#	Article	IF	Citations
181	Lithium, an Infrequently Used Medication. Canadian Journal of Psychiatry, 2019, 65, 070674371989071.	1.9	О
182	Depression and the risk of rheumatoid arthritis. Current Opinion in Rheumatology, 2019, 31, 279-284.	4.3	75
183	Burden of Mental, Neurological, Substance Use Disorders and Self-Harm: Counting the Cards, or Shuffling the Deck?. Canadian Journal of Psychiatry, 2019, 65, 070674371989270.	1.9	0
184	Major depressive episodes and mortality in the Canadian household population. Journal of Affective Disorders, 2019, 242, 165-171.	4.1	8
185	Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom Between 1995 and 2010. Arthritis Care and Research, 2019, 71, 1525-1529.	3.4	5
186	Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata. JAMA Dermatology, 2019, 155, 475.	4.1	40
187	Vitiligo and major depressive disorder: A bidirectional population-based cohort study. Journal of the American Academy of Dermatology, 2019, 80, 1371-1379.	1.2	34
188	Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology, 2019, 92, .	1.1	79
189	Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. Gut, 2019, 68, 1606-1612.	12.1	155
190	Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. Depression and Anxiety, 2019, 36, 82-92.	4.1	16
191	Adherence to and Persistence with Antidepressant Medication during Pregnancy: Does It Differ by the Class of Antidepressant Medication Prescribed?. Canadian Journal of Psychiatry, 2019, 64, 199-208.	1.9	13
192	Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiology and Psychiatric Sciences, 2019, 28, 333-342.	3.9	91
193	Workplace Mental Health Training in Health Care: Key Ingredients of Implementation. Canadian Journal of Psychiatry, 2018, 63, 834-841.	1.9	27
194	Depressive Symptomatology, Syndromal Depression, and HIV-Associated Neurocognitive Disorder (HAND). Canadian Journal of Psychiatry, 2018, 63, 284-286.	1.9	0
195	Beyond Silence: A Randomized, Parallel-Group Trial Exploring the Impact of Workplace Mental Health Literacy Training with Healthcare Employees. Canadian Journal of Psychiatry, 2018, 63, 826-833.	1.9	57
196	Is depression screening in patients with acne critical?: reply from authors. British Journal of Dermatology, 2018, 179, 227-228.	1.5	0
197	Effects of depression and anxiety on quality of life in five common neurological disorders. General Hospital Psychiatry, 2018, 52, 58-63.	2.4	52
198	Barriers and Facilitators for Guidelines with Depression and Anxiety in Parkinson's Disease or Dementia. Canadian Journal on Aging, 2018, 37, 185-199.	1.1	10

#	Article	IF	Citations
199	Validating screening tools for depression in Parkinson's disease. Movement Disorders, 2018, 33, 1184-1186.	3.9	9
200	The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1867-1875.	1.9	84
201	No Obesity Paradox in Pediatric Patients With Dilated Cardiomyopathy. JACC: Heart Failure, 2018, 6, 222-230.	4.1	14
202	The prevalence of anxiety and associated factors in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 35-39.	2.0	47
203	Risk of depression among patients with acne in the U.K.: a population-based cohort study. British Journal of Dermatology, 2018, 178, e194-e195.	1.5	43
204	Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 970-978.	3.4	100
205	Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. General Hospital Psychiatry, 2018, 51, 71-78.	2.4	19
206	The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 20, 9-15.	2.0	113
207	Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care. Canadian Journal of Neurological Sciences, 2018, 45, 188-198.	0.5	10
208	Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology, 2018, 90, e419-e427.	1.1	67
209	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. British Journal of Psychiatry, 2018, 212, 377-385.	2.8	53
210	Cardiac and inflammatory biomarkers in perinatally HIV-infected and HIV-exposed uninfected children. Aids, 2018, 32, 1267-1277.	2.2	14
211	Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 1641-1648.	1.9	21
212	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology, 2018, 90, e1316-e1323.	1.1	136
213	Patterns of association of chronic medical conditions and major depression. Epidemiology and Psychiatric Sciences, 2018, 27, 42-50.	3.9	41
214	Burnout in dermatology residents: a Canadian perspective. British Journal of Dermatology, 2018, 178, 270-271.	1.5	18
215	Prevalence of psychological distress: How do Australia and Canada compare?. Australian and New Zealand Journal of Psychiatry, 2018, 52, 227-238.	2.3	26
216	Efficacy and adverse events of oral isotretinoin for acne: a systematic review. British Journal of Dermatology, 2018, 178, 76-85.	1.5	110

#	Article	IF	CITATIONS
217	Examining the Application of the Opening Minds Survey in the Community Health Centre Setting. Canadian Journal of Psychiatry, 2018, 63, 30-36.	1.9	14
218	Patterns of change in anxiety and depression during pregnancy predict preterm birth. Journal of Affective Disorders, 2018, 227, 71-78.	4.1	24
219	Systemic retinoids and psychiatric disorders in patients with skin diseases: a multifactorial relationship. British Journal of Dermatology, 2018, 178, 305-305.	1.5	1
220	Major depression and secondhand smoke exposure. Journal of Affective Disorders, 2018, 225, 260-264.	4.1	34
221	Does age matter? Comparing postâ€treatment psychosocial outcomes in young adult and older adult cancer survivors with their cancerâ€free peers. Psycho-Oncology, 2018, 27, 1404-1411.	2.3	59
222	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 47-61.	2.3	9
223	The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37.	2.3	43
224	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. International Journal of MS Care, 2018, 20, 76-84.	1.0	35
225	Cardiac status of perinatally HIV-infected children. Aids, 2018, 32, 2337-2346.	2.2	8
226	Global Burden of Disease Study trends for Canada from 1990 to 2016. Cmaj, 2018, 190, E1296-E1304.	2.0	43
227	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
228	The "Clinician's illusion―and the epidemiology, diagnosis and treatment of depressive disorders. BMC Psychiatry, 2018, 18, 395.	2.6	4
229	Controlled trial of the impact of a BC adult mental health practice support program (AMHPSP) on primary health care professionals' management of depression. BMC Family Practice, 2018, 19, 183.	2.9	4
230	Patient satisfaction with epilepsy surgery: what is important to patients?. Epileptic Disorders, 2018, 20, 364-373.	1.3	13
231	Diagnostic accuracy of the Geriatric Depression Scale-30, Geriatric Depression Scale-15, Geriatric Depression Scale-5 and Geriatric Depression Scale-4 for detecting major depression: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2018, 8, e026598.	1.9	24
232	Risk of depression among patients with acne: A population-based cohort study using The Health Improvement Network (THIN) database. Journal of the American Academy of Dermatology, 2018, 79, AB247.	1.2	0
233	Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review. Bipolar Disorders, 2018, 20, 583-593.	1.9	17
234	Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2018, 26, 124-156.	2.0	33

#	Article	IF	Citations
235	Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy: A population-based study. Journal of the American Academy of Dermatology, 2018, 79, AB233.	1.2	0
236	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. Neuroepidemiology, 2018, 51, 1-10.	2.3	18
237	The antidepressant mirtazapine improves survival in patients with primary biliary cholangitis. Journal of Hepatology, 2018, 68, S214-S215.	3.7	0
238	The impact of depression and antidepressant usage on primary biliary cholangitis clinical outcomes. PLoS ONE, 2018, 13, e0194839.	2.5	22
239	Social support and maternal mental health at 4 months and 1 year postpartum: analysis from the All Our Families cohort. Journal of Epidemiology and Community Health, 2018, 72, 933-939.	3.7	48
240	Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. General Hospital Psychiatry, 2018, 53, 65-72.	2.4	73
241	Factors associated with perceived need for mental health care in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 25, 179-185.	2.0	14
242	The effect of child hunger on educational attainment and early childbearing outcomes in a longitudinal population sample of Canadian youth. Paediatrics and Child Health, 2018, 23, e77-e84.	0.6	2
243	Safety of psychotropic medicines: looking beyond randomised evidence. Epidemiology and Psychiatric Sciences, 2018, 27, 529-530.	3.9	1
244	Second-generation antipsychotics and metabolic side-effects: Canadian population-based study. BJPsych Open, 2018, 4, 256-261.	0.7	8
245	Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study. RMD Open, 2018, 4, e000670.	3.8	48
246	Prescription trends and psychiatric symptoms following first receipt of one of seven common antiepileptic drugs in general practice. Epilepsy and Behavior, 2018, 84, 49-55.	1.7	10
247	Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study. RMD Open, 2018, 4, e000668.	3.8	3
248	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. JMIR Research Protocols, 2018, 7, e15.	1.0	38
249	Canadian trends in opioid-related mortality and disability from opioid use disorder from 1990 to 2014 through the lens of the Global Burden of Disease Study. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2018, 38, 234-243.	1.1	43
250	Seasonal variation in major depressive episode prevalence in Canada. Epidemiology and Psychiatric Sciences, 2017, 26, 169-176.	3.9	34
251	Descriptive Epidemiology of Generalized Anxiety Disorder in Canada. Canadian Journal of Psychiatry, 2017, 62, 24-29.	1.9	40
252	Depression screening tools in persons with epilepsy: A systematic review of validated tools. Epilepsia, 2017, 58, 695-705.	5.1	106

#	Article	IF	Citations
253	Increased incidence and prevalence of psoriasis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 13, 81-86.	2.0	28
254	Association of Depression and Treated Depression With Epilepsy and Seizure Outcomes. JAMA Neurology, 2017, 74, 533.	9.0	139
255	Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study. Journal of Investigative Dermatology, 2017, 137, 828-835.	0.7	70
256	Impact of Skill-Based Approaches in Reducing Stigma in Primary Care Physicians: Results from a Double-Blind, Parallel-Cluster, Randomized Controlled Trial. Canadian Journal of Psychiatry, 2017, 62, 327-335.	1.9	34
257	Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry, 2017, 16, 90-99.	10.4	352
258	Differences in Presentation and Outcomes Between Children With Familial Dilated Cardiomyopathy and Children With Idiopathic Dilated Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	30
259	Mind the gap: Exploring information gaps for the development of an online resource hub for epilepsy and Behavior, 2017, 70, 18-23.	1.7	9
260	Selective Cutoff Reporting in Studies of Diagnostic Test Accuracy: A Comparison of Conventional and Individual-Patient-Data Meta-Analyses of the Patient Health Questionnaire-9 Depression Screening Tool. American Journal of Epidemiology, 2017, 185, 954-964.	3.4	45
261	Prevalence of Depression in Patients With Mild Cognitive Impairment. JAMA Psychiatry, 2017, 74, 58.	11.0	342
262	Determinants and incidence of depression in multiple sclerosis: A prospective cohort study. Journal of Psychosomatic Research, 2017, 99, 169-176.	2.6	28
263	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
264	Major depression and non-specific distress following smoking cessation in the Canadian general population. Journal of Affective Disorders, 2017, 218, 182-187.	4.1	13
265	Prevalence of Psychiatric Disorders is Increased Five Years before the Diagnosis in IBD. Gastroenterology, 2017, 152, S973.	1.3	3
266	Evaluating Mental Health Literacy in the Workplace: Development and Psychometric Properties of a Vignette-Based Tool. Journal of Occupational Rehabilitation, 2017, 27, 601-611.	2.2	20
267	Efficacy and tolerability of lithium in treating acute mania in youth with bipolar disorder: protocol for a systematic review. International Journal of Bipolar Disorders, 2017, 5, 22.	2.2	5
268	The prevalence of depression and the accuracy of depression screening tools in migraine patients. General Hospital Psychiatry, 2017, 48, 25-31.	2.4	21
269	Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies. Drug Safety, 2017, 40, 771-781.	3.2	136
270	Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2017, 23, 425-434.	0.9	75

#	Article	IF	CITATIONS
271	The prevalence of anxiety and associated factors in persons with epilepsy. Epilepsia, 2017, 58, e107-e110.	5.1	59
272	Trends in antidepressant prescribing to children and adolescents in <scp>Canadian</scp> primary care: <scp>A</scp> timeâ€series analysis. Pharmacoepidemiology and Drug Safety, 2017, 26, 1093-1099.	1.9	17
273	Age of Onset of Mental Disorders. Canadian Journal of Psychiatry, 2017, 62, 235-236.	1.9	19
274	Depression in epilepsy, migraine, and multiple sclerosis. Neurology: Clinical Practice, 2017, 7, 118-127.	1.6	13
275	The impact of seizures on epilepsy outcomes: A national, communityâ€based survey. Epilepsia, 2017, 58, 764-771.	5.1	53
276	The pervasive effect of youth self-report of hunger on depression over 6Âyears of follow up. Social Psychiatry and Psychiatric Epidemiology, 2017, 52, 537-547.	3.1	23
277	Is the prevalence of major depression increasing in the Canadian adolescent population? Assessing trends from 2000 to 2014. Journal of Affective Disorders, 2017, 210, 22-26.	4.1	35
278	The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: A systematic review and meta-analysis. Depression and Anxiety, 2017, 34, 217-226.	4.1	80
279	Prevalence and incidence of epilepsy. Neurology, 2017, 88, 296-303.	1.1	1,141
280	Serotonin reuptake inhibitors and mortality in epilepsy: A linked primaryâ€care cohort study. Epilepsia, 2017, 58, 2002-2009.	5.1	8
281	Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children. Journal of the American College of Cardiology, 2017, 70, 2240-2247.	2.8	24
282	Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome. Journal of Clinical Psychopharmacology, 2017, 37, 498-504.	1.4	21
283	Does Lowering Heart Rate Improve Outcomes in Children With DilatedÂCardiomyopathy and ChronicÂHeart Failure?. Journal of the American College of Cardiology, 2017, 70, 1273-1275.	2.8	4
284	Depression Screening and Health Outcomes in Children and Adolescents: A Systematic Review. Canadian Journal of Psychiatry, 2017, 62, 813-817.	1.9	18
285	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
286	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589
287	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
288	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578

#	Article	IF	CITATIONS
289	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	13.7	1,879
290	Mental health and chronic diseases: a challenge to be faced from a new perspective. International Review of Psychiatry, 2017, 29, 373-376.	2.8	14
291	Under-diagnosis of mood disorders in Canada. Epidemiology and Psychiatric Sciences, 2017, 26, 414-423.	3.9	19
292	The depression and marital status relationship is modified by both age and gender. Journal of Affective Disorders, 2017, 223, 65-68.	4.1	114
293	Disaster Management and Farm Family Mental Health: The BSE Crisis as a Case Study. Prehospital and Disaster Medicine, 2017, 32, S185-S186.	1.3	0
294	Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. Journal of Psychosomatic Research, 2017, 101, 17-23.	2.6	131
295	Analysis of myocardial fibrosis in children with hypertrophic cardiomyopathy: A report from the pediatric cardiomyopathy registry. Progress in Pediatric Cardiology, 2017, 46, 33.	0.4	0
296	Author response: Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology, 2017, 89, 641-642.	1.1	5
297	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology, 2017, 48, 124-130.	2.3	6
298	Online tools for individuals with depression and neurologic conditions. Neurology: Clinical Practice, 2017, 7, 344-353.	1.6	4
299	Survival Without Cardiac Transplantation Among Children With DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 2663-2673.	2.8	59
300	Comorbidity increases the risk of relapse in multiple sclerosis. Neurology, 2017, 89, 2455-2461.	1.1	77
301	Depression in multiple sclerosis. International Review of Psychiatry, 2017, 29, 463-472.	2.8	146
302	Homelessness and Mental Health. Canadian Journal of Psychiatry, 2017, 62, 440-441.	1.9	7
303	A comparison of recommendations and received treatment for mood and anxiety disorders in a representative national sample. BMC Psychiatry, 2017, 17, 155.	2.6	1
304	The Prevalence of Major Depressive Episodes Is Higher in Urban Regions of Canada. Canadian Journal of Psychiatry, 2017, 62, 57-61.	1.9	15
305	Major Depression Prevalence Increases with Latitude in Canada. Canadian Journal of Psychiatry, 2017, 62, 62-66.	1.9	12
306	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. Multiple Sclerosis Journal, 2017, 23, 588-596.	3.0	44

#	Article	IF	Citations
307	Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Research Notes, 2017, 10, 619.	1.4	38
308	Hospital treatment costs and length of stay associated with hypertension and multimorbidity after hemorrhagic stroke. BMC Neurology, 2017, 17, 158.	1.8	31
309	Discriminative ability of quality of life measures in multiple sclerosis. Health and Quality of Life Outcomes, 2017, 15, 246.	2.4	11
310	A T-type channel-calmodulin complex triggers αCaMKII activation. Molecular Brain, 2017, 10, 37.	2.6	22
311	Minimal sufficient balance randomization for sequential randomized controlled trial designs: results from the ESCAPE trial. Trials, 2017, 18, 516.	1.6	8
312	Featured Canadian Research on Child, Adolescent, and Young Adult Psychiatry. Canadian Journal of Psychiatry, 2017, 62, 810-812.	1.9	0
313	Mobile-based blended learning for capacity building of health providers in rural Afghanistan. MHealth, 2017, 3, 14-14.	1.6	7
314	A comparison of bivariate, multivariate randomâ€effects, and Poisson correlated gammaâ€frailty models to metaâ€analyze individual patient data of ordinal scale diagnostic tests. Biometrical Journal, 2017, 59, 1317-1338.	1.0	4
315	Fighting Stigma in Canada: Opening Minds Anti-Stigma Initiative. , 2017, , 237-261.		5
316	Using OSCEs with simulation to maximise student learning and assess competencies in psychology: A pilot study. Focus on Health Professional Education, 2017, 18, 61.	0.8	6
317	Protocol: a cluster randomised control trial study exploring stigmatisation and recovery-based perspectives regarding mental illness and substance use problems among primary healthcare providers across Toronto, Ontario. BMJ Open, 2017, 7, e017044.	1.9	9
318	Self-management of mood and/or anxiety disorders through physical activity/exercise. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2017, 37, 149-159.	1.1	31
319	Re:. Nutricion Hospitalaria, 2017, 34, 1006-1008.	0.3	2
320	Trends in binge drinking in Canada from 1996 to 2013: a repeated cross-sectional analysis. CMAJ Open, 2016, 4, E599-E604.	2.4	12
321	Implementing a data sharing culture. Epidemiology and Psychiatric Sciences, 2016, 25, 289-290.	3.9	15
322	Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. BMC Research Notes, 2016, 9, 404.	1.4	40
323	The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis. Clinical and Translational Gastroenterology, 2016, 7, e165.	2.5	15
324	Towards a clinically informed, dataâ€driven definition of elderly onset epilepsy. Epilepsia, 2016, 57, 298-305.	5.1	26

#	Article	lF	CITATIONS
325	Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis. International Journal of Geriatric Psychiatry, 2016, 31, 1151-1171.	2.7	111
326	EDUCATIONAL ATTAINMENT AS A PROTECTIVE FACTOR FOR PSYCHIATRIC DISORDERS: FINDINGS FROM A NATIONALLY REPRESENTATIVE LONGITUDINAL STUDY. Depression and Anxiety, 2016, 33, 1013-1022.	4.1	48
327	Childhood adversity and subsequent mental health status in adulthood: screening for associations using two linked surveys. Epidemiology and Psychiatric Sciences, 2016, 25, 160-170.	3.9	15
328	Determinants of rebound burst responses in rat cerebellar nuclear neurons to physiological stimuli. Journal of Physiology, 2016, 594, 985-1003.	2.9	23
329	Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. BMJ Open, 2016, 6, e011913.	1.9	22
330	Declining Incidence of Systolic Left Ventricular Dysfunction in Human Immunodeficiency Virus–Infected Individuals Treated With Highly Active Antiretroviral Therapy. American Journal of Cardiology, 2016, 117, 1194-1195.	1.6	12
331	Consistency in adult reporting of adverse childhood experiences. Psychological Medicine, 2016, 46, 543-549.	4.5	198
332	Frailty Trajectories After Treatment for Coronary Artery Disease in Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 230-238.	2.2	20
333	Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. Multiple Sclerosis and Related Disorders, 2016, 8, 86-92.	2.0	14
334	Perceived Stigma among Recipients of Mental Health Care in the General Canadian Population. Canadian Journal of Psychiatry, 2016, 61, 480-488.	1.9	55
335	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 120-128.	1.6	42
336	The association between major depression prevalence and sex becomes weaker with age. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 203-210.	3.1	25
337	Characterization of Disability in Canadians with Mental Disorders Using an Abbreviated Version of a <i>DSM-5</i> Emerging Measure: The 12-Item WHO Disability Assessment Schedule (WHODAS) 2.0. Canadian Journal of Psychiatry, 2016, 61, 227-235.	1.9	37
338	Scaling-up of treatment of depression and anxiety. Lancet Psychiatry, the, 2016, 3, 603.	7.4	6
339	Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis. Brain and Behavior, 2016, 6, e00493.	2.2	24
340	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740
341	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
342	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934

#	Article	IF	CITATIONS
343	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	13.7	5,298
344	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
345	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
346	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
347	Comparison of the estimated prevalence of mood and/or anxiety disorders in Canada between self-report and administrative data. Epidemiology and Psychiatric Sciences, 2016, 25, 360-369.	3.9	45
348	Updated CANMAT Guidelines for Treatment of Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 504-505.	1.9	18
349	Guidelines for dementia or Parkinson's disease with depression or anxiety: a systematic review. BMC Neurology, 2016, 16, 244.	1.8	43
350	A grounded theory model for reducing stigma in health professionals in Canada. Acta Psychiatrica Scandinavica, 2016, 134, 53-62.	4.5	86
351	Suicidal ideation in persons with neurological conditions: prevalence, associations and validation of the PHQ-9 for suicidal ideation. General Hospital Psychiatry, 2016, 42, 22-26.	2.4	39
352	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
353	Depressive symptoms and functional decline following coronary interventions in older patients with coronary artery disease: a prospective cohort study. BMC Psychiatry, 2016, 16, 277.	2.6	6
354	Mental Health in the Canadian Armed Forces. Canadian Journal of Psychiatry, 2016, 61, 4S-6S.	1.9	5
355	Progress in Pediatric Cardiology. Progress in Pediatric Cardiology, 2016, 40, 1.	0.4	0
356	Mental disorders and distress: Associations with demographics, remoteness and socioeconomic deprivation of area of residence across Australia. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1169-1179.	2.3	45
357	Accuracy of Depression Screening Tools to Detect Major Depression in Children and Adolescents: A Systematic Review. Canadian Journal of Psychiatry, 2016, 61, 746-757.	1.9	34
358	Validating screening tools for depression in stroke and transient ischemic attack patients. International Journal of Psychiatry in Medicine, 2016, 51, 262-277.	1.8	50
359	Major Depression in Canada: What Has Changed over the Past 10 Years?. Canadian Journal of Psychiatry, 2016, 61, 80-85.	1.9	39
360	Differing trends in the incidence of vascular comorbidity in MS and the general population. Neurology: Clinical Practice, 2016, 6, 201-202.	1.6	0

#	Article	IF	CITATIONS
361	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	6.2	479
362	An investigation into the psychosocial effects of the postictal state. Neurology, 2016, 86, 723-730.	1.1	15
363	Future research directions in pediatric cardiomyopathy. Progress in Pediatric Cardiology, 2016, 40, 35-39.	0.4	1
364	Why is major depression prevalence not changing?. Journal of Affective Disorders, 2016, 190, 93-97.	4.1	34
365	Preventing pediatric cardiomyopathy: a 2015 outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 321-339.	1.5	4
366	Overeating at dinner time among Japanese workers: Is overeating related to stress response and late dinner times?. Appetite, 2016, 101, 8-14.	3.7	12
367	Screening for Depression and Anxiety in Epilepsy. Neurologic Clinics, 2016, 34, 351-361.	1.8	48
368	Long-Term Effects of <i>In Utero</i> Antiretroviral Exposure: Systolic and Diastolic Function in HIV-Exposed Uninfected Youth. AIDS Research and Human Retroviruses, 2016, 32, 621-627.	1.1	17
369	Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology, 2016, 86, 1287-1295.	1.1	79
370	Assessing the role of IKCa channels in generating the sAHP of CA1 hippocampal pyramidal cells. Channels, 2016, 10, 313-319.	2.8	22
371	Health-related quality of life in multiple sclerosis. Neurology, 2016, 86, 1417-1424.	1.1	156
372	Sex differences in comorbidity at diagnosis of multiple sclerosis. Neurology, 2016, 86, 1279-1286.	1.1	86
373	Health-Related Quality of Life and Functional Status Are Associated with Cardiac Status and Clinical Outcome in Children with Cardiomyopathy. Journal of Pediatrics, 2016, 170, 173-180.e4.	1.8	15
374	Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research. Pharmacoeconomics, 2016, 34, 115-126.	3.3	35
375	Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 5, 12-26.	2.0	133
376	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. Multiple Sclerosis Journal, 2016, 22, 685-693.	3.0	27
377	Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey. Journal of Medical Internet Research, 2016, 18, e132.	4.3	28
378	The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2016, 5, e218.	1.0	11

#	Article	IF	CITATIONS
379	Fatigue and Comorbidities in Multiple Sclerosis. International Journal of MS Care, 2016, 18, 96-104.	1.0	38
380	Screening Tools for Anxiety in People with Multiple Sclerosis. International Journal of MS Care, 2016, 18, 273-281.	1.0	24
381	Major depressive disorder: reification and (maybe) rheostasis. Epidemiology and Psychiatric Sciences, 2015, 24, 473-475.	3.9	3
382	The Prevalence of Major Depression is Not Changing. Canadian Journal of Psychiatry, 2015, 60, 31-34.	1.9	40
383	A Canadian Primary Care Sentinel Surveillance Network Study Evaluating Antidepressant Prescribing in Canada from 2006 to 2012. Canadian Journal of Psychiatry, 2015, 60, 564-570.	1.9	20
384	Prevalence of Bipolar I and II Disorder in Canada. Canadian Journal of Psychiatry, 2015, 60, 151-156.	1.9	31
385	Problems from the Past and Prevention for the Future. Canadian Journal of Psychiatry, 2015, 60, 4-5.	1.9	3
386	Psychiatric Epidemiology: It is about Much More Than Prevalence. Canadian Journal of Psychiatry, 2015, 60, 529-530.	1.9	1
387	Validity of four screening scales for major depression in MS. Multiple Sclerosis Journal, 2015, 21, 1064-1071.	3.0	77
388	A Valuable (and Ongoing) Study, the National Trajectory Project Addresses Many Myths about the Verdict of Not Criminally Responsible on Account of Mental Disorder. Canadian Journal of Psychiatry, 2015, 60, 93-95.	1.9	1
389	Healthâ€related behaviors and comorbidities in people with epilepsy: Changes in the past decade. Epilepsia, 2015, 56, 1973-1981.	5.1	17
390	Descriptive Epidemiology of Major Depressive Disorder in Canada in 2012. Canadian Journal of Psychiatry, 2015, 60, 23-30.	1.9	139
391	Correlates of disability related to seizures in persons with epilepsy. Epilepsia, 2015, 56, 1463-1469.	5.1	41
392	The Canadian Journal of Psychiatry in 2014 and beyond. Canadian Journal of Psychiatry, 2015, 60, 1-3.	1.9	10
393	Physical Activity Interventions in Schools for Improving Lifestyle in European Countries. Clinical Practice and Epidemiology in Mental Health, 2015, 11, 77-101.	1.2	49
394	Predictors of Well-Being in Resident Physicians: A Descriptive and Psychometric Study. Journal of Graduate Medical Education, 2015, 7, 70-74.	1.3	75
395	Medical models and metaphors for depression. Epidemiology and Psychiatric Sciences, 2015, 24, 303-308.	3.9	21
396	Functional variants of POC5 identified in patients with idiopathic scoliosis. Journal of Clinical Investigation, 2015, 125, 1124-1128.	8.2	87

#	Article	IF	CITATIONS
397	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
398	Stigma towards borderline personality disorder: effectiveness and generalizability of an anti-stigma program for healthcare providers using a pre-post randomized design. Borderline Personality Disorder and Emotion Dysregulation, 2015, 2, 9.	2.6	50
399	IKCa Channels Are a Critical Determinant of the Slow AHP in CA1 Pyramidal Neurons. Cell Reports, 2015, 11, 175-182.	6.4	64
400	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	7.1	2,269
401	PSYCHOSOCIAL STRESS PARTIALLY MEDIATES THE ASSOCIATION BETWEEN RACE AND PRENATAL DEPRESSIVE SYMPTOMS IN A SAMPLE OF PREGNANT WOMEN IN ALBERTA. Journal of Epidemiology and Community Health, 2015, 69, A4.2-A4.	3.7	0
402	Determinants of disease severity in adults with epilepsy: Results from the Neurological Diseases and Depression Study. Epilepsy and Behavior, 2015, 51, 170-175.	1.7	24
403	Diagnostic accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for detecting major depression in pregnant and postnatal women: protocol for a systematic review and individual patient data meta-analyses. BMJ Open, 2015, 5, e009742.	1.9	46
404	Syndemic Vulnerability, Sexual and Injection Risk Behaviors, and HIV Continuum of Care Outcomes in HIV-Positive Injection Drug Users. AIDS and Behavior, 2015, 19, 684-693.	2.7	56
405	Depression in multiple sclerosis: A long-term longitudinal study. Multiple Sclerosis Journal, 2015, 21, 76-82.	3.0	66
406	Retrospective and prospectively assessed childhood adversity in association with major depression, alcohol consumption and painful conditions. Epidemiology and Psychiatric Sciences, 2015, 24, 158-165.	3.9	67
407	Associations of medical comorbidity, psychosis, pain, and capacity with psychiatric hospital length of stay in geriatric inpatients with and without dementia. International Psychogeriatrics, 2015, 27, 313-321.	1.0	14
408	Elevated Hospitalization Risk of Assisted Living Residents With Dementia in Alberta, Canada. Journal of the American Medical Directors Association, 2015, 16, 568-577.	2.5	34
409	Bupropion confirmed not to cause weight gain in a real-world clinical population. Evidence-Based Mental Health, 2015, 18, 57-57.	4.5	1
410	Cardiomyopathy Phenotypes and Outcomes for Children With Left Ventricular Myocardial Noncompaction: Results From the Pediatric Cardiomyopathy Registry. Journal of Cardiac Failure, 2015, 21, 877-884.	1.7	140
411	Identifying reprioritization response shift in a stroke caregiver population: a comparison of missing data methods. Quality of Life Research, 2015, 24, 529-540.	3.1	12
412	Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks? BMJ, The, 2015, 350, h569-h569.	6.0	9
413	Substance-related and behavioural addiction problems: Two surveys of Canadian adults. Addiction Research and Theory, 2015, 23, 34-42.	1.9	20
414	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2015, 4, 470-476.	2.0	40

#	Article	IF	CITATIONS
415	Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology, 2015, 85, 1972-1979.	1.1	106
416	Prevalence, predictors, and outcomes of cardiorenal syndrome in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. Pediatric Nephrology, 2015, 30, 2177-2188.	1.7	15
417	Seeing is believing: Biological information may reduce mental health stigma amongst physicians. Australian and New Zealand Journal of Psychiatry, 2015, 49, 751-752.	2.3	12
418	Mental illness stigma as a quality-of-care problem. Lancet Psychiatry, the, 2015, 2, 863-864.	7.4	49
419	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
420	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
421	Depression $\hat{a} \in \mathbb{C}$ a common disorder across a broad spectrum of neurological conditions: a cross-sectional nationally representative survey. General Hospital Psychiatry, 2015, 37, 507-512.	2.4	27
422	Beyond silence: protocol for a randomized parallel-group trial comparing two approaches to workplace mental health education for healthcare employees. BMC Medical Education, 2015, 15, 78.	2.4	29
423	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	13.7	5,847
424	Social judgments of behavioral versus substance-related addictions: A population-based study. Addictive Behaviors, 2015, 42, 24-31.	3.0	45
425	Long-Term Persistence with Injectable Therapy in Relapsing-Remitting Multiple Sclerosis: An 18-Year Observational Cohort Study. PLoS ONE, 2015, 10, e0123824.	2.5	25
426	The Wisdom of Crowds (Vox Populi) and Antidepressant Use. Clinical Practice and Epidemiology in Mental Health, 2015, $11$ , $1$ -3.	1.2	2
427	The Wisdom of Crowds (Vox Populi) and Antidepressant Use. Clinical Practice and Epidemiology in Mental Health, $2015,11,1$ -3.	1.2	2
428	Exploration of Undertreatment and Patterns of Treatment of Depression in Multiple Sclerosis. International Journal of MS Care, 2015, 17, 292-300.	1.0	36
429	Factors Associated with Early Deterioration after Spontaneous Intracerebral Hemorrhage: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e96743.	2.5	65
430	The Role of Systematic Reviews and Meta-Analyses of Incidence and Prevalence Studies in Neuroepidemiology. Neuroepidemiology, 2014, 42, 16-24.	2.3	21
431	The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. Systematic Reviews, 2014, 3, 124.	5.3	71
432	The Global Burden of Disease 2010 update: keeping mental health in the spotlight. Epidemiology and Psychiatric Sciences, 2014, 23, 255-257.	3.9	3

#	Article	IF	Citations
433	Cost of Spontaneous Intracerebral Hemorrhage in Canada During 1 Decade. Stroke, 2014, 45, 284-286.	2.0	23
434	The diagnosis of depression and its treatment in Canadian primary care practices: an epidemiological study. CMAJ Open, 2014, 2, E337-E342.	2.4	35
435	Patterns and frequency of the treatment of depression in persons with epilepsy. Epilepsy and Behavior, 2014, 39, 59-64.	1.7	38
436	A comparison of tissue oxygen saturation measurements by 2 different nearâ€infrared spectroscopy monitors in 21 healthy dogs. Journal of Veterinary Emergency and Critical Care, 2014, 24, 536-544.	1.1	8
437	Patient satisfaction with care in epilepsy: How much do we know?. Epilepsia, 2014, 55, 448-455.	5.1	14
438	Systematic review and assessment of validated case definitions for depression in administrative data. BMC Psychiatry, 2014, 14, 289.	2.6	172
439	A prediction algorithm for first onset of major depression in the general population: development and validation. Journal of Epidemiology and Community Health, 2014, 68, 418-424.	3.7	41
440	Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectrums, 2014, 19, 496-508.	1.2	74
441	Antidepressant dose and the risk of deliberate self-harm. Epidemiology and Psychiatric Sciences, 2014, 23, 329-331.	3.9	5
442	Prevalence and risk factors for suicidal ideation in a multiple sclerosis population. Journal of Psychosomatic Research, 2014, 76, 312-316.	2.6	33
443	Depression and painful conditions: patterns of association with health status and health utility ratings in the general population. Quality of Life Research, 2014, 23, 363-371.	3.1	2
444	An overview of the statistical methods reported by studies using the Canadian community health survey. BMC Medical Research Methodology, 2014, 14, 15.	3.1	12
445	Prevalence of neurological conditions across the continuum of care based on interRAI assessments. BMC Health Services Research, 2014, 14, 29.	2.2	16
446	Point prevalence and correlates of depression in a national community sample with multiple sclerosis. General Hospital Psychiatry, 2014, 36, 352-354.	2.4	25
447	An all-GaN differential driver for a 60 V GaN-based power amplifier with 1 GHz switching frequency. , 2014, , .		6
448	How Canadian Service Providers Understand, and Incorporate, Biomedical Knowledge of HIV into their Prevention Work and their Own Sexual Practices. AIDS Research and Human Retroviruses, 2014, 30, A275-A275.	1.1	0
449	DEVELOPMENT AND VALIDATION OF A PREDICTION ALGORITHM FOR USE BY HEALTH PROFESSIONALS IN PREDICTION OF RECURRENCE OF MAJOR DEPRESSION. Depression and Anxiety, 2014, 31, 451-457.	4.1	30
450	Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS. Neurology, 2014, 82, 174-181.	1.1	189

#	Article	IF	CITATIONS
451	Validating screening tools for depression in epilepsy. Epilepsia, 2014, 55, 1642-1650.	5.1	59
452	RECURRENCE OF MAJOR DEPRESSIVE EPISODES IS STRONGLY DEPENDENT ON THE NUMBER OF PREVIOUS EPISODES. Depression and Anxiety, 2014, 31, 72-76.	4.1	35
453	The Expression Pattern of a Cav3-Kv4 Complex Differentially Regulates Spike Output in Cerebellar Granule Cells. Journal of Neuroscience, 2014, 34, 8800-8812.	<b>3.</b> 6	28
454	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
455	Opening Minds Stigma Scale for Health Care Providers (OMS-HC): Examination of psychometric properties and responsiveness. BMC Psychiatry, 2014, 14, 120.	2.6	122
456	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	13.7	1,230
457	Changing Perceptions of Mental Health in Canada. Canadian Journal of Psychiatry, 2014, 59, 591-596.	1.9	7
458	Key Ingredients of Anti-Stigma Programs for Health Care Providers: A Data Synthesis of Evaluative Studies. Canadian Journal of Psychiatry, 2014, 59, 19-26.	1.9	173
459	Antidepressant Use in Canada Has Stopped Increasing. Canadian Journal of Psychiatry, 2014, 59, 609-614.	1.9	11
460	Opening Minds in Canada: Background and Rationale. Canadian Journal of Psychiatry, 2014, 59, 8-12.	1.9	56
461	Opening Minds in Canada: Targeting Change. Canadian Journal of Psychiatry, 2014, 59, 13-18.	1.9	94
462	Important Messages for Clinical Care and Health Policy on Suicide. Canadian Journal of Psychiatry, 2014, 59, 509-510.	1.9	0
463	Reviews and Perspectives. Canadian Journal of Psychiatry, 2014, 59, 1-2.	1.9	5
464	Delicate Considerations and Blunt Instruments. Canadian Journal of Psychiatry, 2014, 59, 117-117.	1.9	1
465	Support, Patience, and Expectancy: Therapeutic Options Alongside Intensified Treatments for Depression?. Canadian Journal of Psychiatry, 2014, 59, 347-348.	1.9	1
466	Stigma in Canada: Results from a Rapid Response Survey. Canadian Journal of Psychiatry, 2014, 59, 27-33.	1.9	51
467	P3-285: ACUTE CARE TRANSITIONS AND OUTCOMES AMONG ASSISTED LIVING RESIDENTS WITH AND WITHOUT DEMENTIA. , 2014, 10, P735-P736.		1
468	Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients. Drugs and Aging, 2013, 30, 569-585.	2.7	14

#	Article	IF	CITATIONS
469	Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair. CNS Neuroscience and Therapeutics, 2013, 19, 737-744.	3.9	44
470	Childhood and adult stressors and major depression risk: interpreting interactions with the sufficient-component cause model. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 927-933.	3.1	16
471	Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurology, 2013, 13, 16.	1.8	122
472	Major depression epidemiology from a diathesis-stress conceptualization. BMC Psychiatry, 2013, 13, 19.	2.6	30
473	Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. Multiple Sclerosis and Related Disorders, 2013, 2, 355-361.	2.0	34
474	Development and validation of prediction algorithms for major depressive episode in the general population. Journal of Affective Disorders, 2013, 151, 39-45.	4.1	33
475	The case for vitamin D supplementation in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2013, 2, 281-306.	2.0	13
476	The Pharmacoepidemiology of Selective Serotonin Reuptake Inhibitors for Children and Adolescents in Canada from 2005 to 2009: A Database Analysis. Paediatric Drugs, 2013, 15, 319-327.	3.1	27
477	Bistability in Purkinje neurons: Ups and downs in cerebellar research. Neural Networks, 2013, 47, 18-31.	5.9	40
478	Depression in epilepsy. Neurology, 2013, 80, 590-599.	1.1	308
479	Stress and development of depression and heavy drinking in adulthood: moderating effects of childhood trauma. Social Psychiatry and Psychiatric Epidemiology, 2013, 48, 265-274.	3.1	33
480	RECURRENCE RISK IN MAJOR DEPRESSION. Depression and Anxiety, 2013, 30, 1-4.	4.1	16
481	Depression and suicide ideation in late adolescence and early adulthood are an outcome of child hunger. Journal of Affective Disorders, 2013, 150, 123-129.	4.1	147
482	GBD 2010 country results: a global public good. Lancet, The, 2013, 381, 965-970.	13.7	36
483	Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychological Medicine, 2013, 43, 471-481.	4.5	860
484	The Ca <sub>v</sub> 3–K <sub>v</sub> 4 Complex Acts as a Calcium Sensor to Maintain Inhibitory Charge Transfer during Extracellular Calcium Fluctuations. Journal of Neuroscience, 2013, 33, 7811-7824.	3.6	44
485	The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study. Neuroepidemiology, 2013, 40, 85-92.	2.3	62
486	Relationship Between Relapse and Hospitalization in First-Episode Psychosis. Psychiatric Services, 2013, 64, 796-799.	2.0	38

#	Article	IF	Citations
487	Modeling interactions between voltage-gated Ca <sup>2+</sup> channels and KCa1.1 channels. Channels, 2013, 7, 524-529.	2.8	15
488	Receiving Workplace Mental Health Accommodations and the Outcome of Mental Disorders in Employees With a Depressive and/or Anxiety Disorder. Journal of Occupational and Environmental Medicine, 2013, 55, 1293-1299.	1.7	25
489	Work Reintegration for Veterans With Mental Disorders: A Systematic Literature Review to Inform Research. Physical Therapy, 2013, 93, 1163-1174.	2.4	21
490	Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Medicine, 2013, 10, e1001547.	8.4	2,377
491	High Positive Psychiatrie Screening Rates in an Urban Homeless Population. Canadian Journal of Psychiatry, 2013, 58, 353-360.	1.9	8
492	Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Services Research, 2013, 13, 457.	2.2	60
493	The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada. Canadian Journal of Neurological Sciences, 2013, 40, 824-831.	0.5	53
494	Ethical and Legal Considerations for Canadian Registries. Canadian Journal of Neurological Sciences, 2013, 40, S5-S22.	0.5	8
495	Reducing the stigma of mental illness in undergraduate medical education: a randomized controlled trial. BMC Medical Education, 2013, 13, 141.	2.4	112
496	Low Voltage Activation of KCa1.1 Current by Cav3-KCa1.1 Complexes. PLoS ONE, 2013, 8, e61844.	2.5	48
497	The Reliability and Sensitivity of the National Institutes of Health Stroke Scale for Spontaneous Intracerebral Hemorrhage in an Uncontrolled Setting. PLoS ONE, 2013, 8, e84702.	2.5	12
498	Recreational Physical Activity Ameliorates Some of the Negative Impact of Major Depression on Health-Related Quality of Life. Frontiers in Psychiatry, 2013, 4, 22.	2.6	9
499	Signal processing by T-type calcium channel interactions in the cerebellum. Frontiers in Cellular Neuroscience, 2013, 7, 230.	3.7	20
500	The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010. PLoS ONE, 2013, 8, e69637.	2.5	242
501	Mental Health Practice and Attitudes of Family Physicians Can Be Changed!. , 2013, 17, 14-17.		37
502	Depression as a predictor of occupational transition in a multiple sclerosis cohort. Functional Neurology, 2013, 28, 275-80.	1.3	7
503	Review: depression is associated with an increased risk of stroke in adults. Evidence-Based Mental Health, 2012, 15, 6-6.	4.5	1
504	Rethinking recommendations for screening for depression in primary care. Cmaj, 2012, 184, 413-418.	2.0	184

#	Article	IF	Citations
505	Managing pathologic aggression in people with psychotic disorders. Journal of Psychiatry and Neuroscience, 2012, 37, E3-E4.	2.4	3
506	Intermediate conductance calcium-activated potassium channels modulate summation of parallel fiber input in cerebellar Purkinje cells. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2601-2606.	7.1	85
507	A Population-based Longitudinal Study on Work Environmental Factors and the Risk of Major Depressive Disorder. American Journal of Epidemiology, 2012, 176, 52-59.	3.4	95
508	The Multiple Sclerosis Depression Rating Scale. Expert Review of Neurotherapeutics, 2012, 12, 1053-1055.	2.8	3
509	Evaluation of the 9–Item Patient Health Questionnaire (PHQ–9) as an Assessment Instrument for Symptoms of Depression in Patients with Multiple Sclerosis. Postgraduate Medicine, 2012, 124, 69-77.	2.0	62
510	Utilization of General and Specialized Cardiac Care by People With Schizophrenia. Psychiatric Services, 2012, 63, 237-242.	2.0	13
511	Re-rethinking the article by Thombs and colleagues: Figure 1:. Cmaj, 2012, 184, 438.2-439.	2.0	2
512	Predictors of 1-year outcomes of major depressive disorder among individuals with a lifetime diagnosis: a population-based study. Psychological Medicine, 2012, 42, 327-334.	4.5	22
513	Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Multiple Sclerosis Journal, 2012, 18, 1310-1319.	3.0	109
514	$\hat{Al^2}$ neurotoxicity depends on interactions between copper ions, prion protein, and <i>N</i> -methyl <scp>d</scp> -aspartate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1737-1742.	7.1	209
515	Business mergers and acquisitions and the risk of mental disorders: a population-based study. Occupational and Environmental Medicine, 2012, 69, 569-573.	2.8	9
516	Disability in a Community Population with MS with and without Mental Disorders. International Journal of Psychiatry in Medicine, 2012, 43, 51-65.	1.8	4
517	Substantial Changes in Prescription Recommendations for Bipolar Disorder in Canada: 2002–2010. Canadian Journal of Psychiatry, 2012, 57, 263-268.	1.9	9
518	Les recommandations thérapeutiques relatives aux effets secondaires extrapyramidaux associés à l'utilisation d'antipsychotiques de deuxiÙme génération chez les enfants et les adolescents. Paediatrics and Child Health, 2012, 17, 22B-30B.	0.6	4
519	Prevalence Inflation. Canadian Journal of Psychiatry, 2012, 57, 649-650.	1.9	0
520	A Review of Pharmacoepidemiologic Studies of Antipsychotic Use in Children and Adolescents. Canadian Journal of Psychiatry, 2012, 57, 717-721.	1.9	60
521	A Dynamic View of Depressive Symptoms and Neurocognitive Change Among Patients With Coronary Artery Disease. Archives of General Psychiatry, 2012, 69, 244.	12.3	29
522	Is Mental Health in the Canadian Population Changing over Time?. Canadian Journal of Psychiatry, 2012, 57, 324-331.	1.9	37

#	Article	IF	CITATIONS
523	Perceived Discrimination among People with Self-Reported Emotional, Psychological, or Psychiatric Conditions in a Population-Based Sample of Canadians Reporting a Disability. Canadian Journal of Psychiatry, 2012, 57, 102-110.	1.9	11
524	Health Status, Stress and Life Satisfaction in a Community Population with MS. Canadian Journal of Neurological Sciences, 2012, 39, 206-212.	0.5	9
525	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
526	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
527	Patterns of disability, care needs, and quality of life of people with Parkinson's disease in a general population sample. Parkinsonism and Related Disorders, 2012, 18, 828-832.	2.2	29
528	ALCOHOL CONSUMPTION AND MAJOR DEPRESSION IN THE GENERAL POPULATION: THE CRITICAL IMPORTANCE OF DEPENDENCE. Depression and Anxiety, 2012, 29, 1058-1064.	4.1	55
529	Effectiveness of contact-based education for reducing mental illness-related stigma in pharmacy students. BMC Medical Education, 2012, 12, 120.	2.4	132
530	Comparing frailty measures in their ability to predict adverse outcome among older residents of assisted living. BMC Geriatrics, 2012, 12, 56.	2.7	93
531	The development and psychometric properties of a new scale to measure mental illness related stigma by health care providers: The opening minds scale for Health Care Providers (OMS-HC). BMC Psychiatry, 2012, 12, 62.	2.6	151
532	Synthesis through Simulation: Insights on the Epidemiology of Mood and Anxiety Disorders in Canada. Canadian Journal of Psychiatry, 2012, 57, 765-771.	1.9	4
533	Influence of somatic symptoms on PHQ-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. Arthritis Care and Research, 2012, 64, n/a-n/a.	3.4	22
534	Recall of recent and more remote depressive episodes in a prospective cohort study. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 691-696.	3.1	46
535	Epilepsy is associated with unmet health care needs compared to the general population despite higher health resource utilization—A Canadian populationâ€based study. Epilepsia, 2012, 53, 291-300.	5.1	34
536	Depressive episode characteristics and subsequent recurrence risk. Journal of Affective Disorders, 2012, 140, 277-284.	4.1	22
537	A Populationâ€Based Longitudinal Community Study of Major Depression and Migraine. Headache, 2012, 52, 422-432.	3.9	65
538	Persistent heavy smoking as risk factor for major depression (MD) incidence – Evidence from a longitudinal Canadian cohort of the National Population Health Survey. Journal of Psychiatric Research, 2012, 46, 436-443.	3.1	46
539	Three job-related stress models and depression: a population-based study. Social Psychiatry and Psychiatric Epidemiology, 2012, 47, 185-193.	3.1	55
540	Perceived Met and Unmet Health-Care Needs in a Community Population with Multiple Sclerosis. International Journal of MS Care, 2012, 14, 2-8.	1.0	34

#	Article	IF	Citations
541	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of Clinical Psychiatry, 2012, 24, 91-109.	0.6	56
542	Predictors of long-term prognosis of depression. Cmaj, 2011, 183, 1969-1976.	2.0	81
543	Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children. Drug Safety, 2011, 34, 651-668.	3.2	117
544	Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. European Psychiatry, 2011, 26, 327-332.	0.2	17
545	Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatrics and Child Health, 2011, 16, 581-589.	0.6	116
546	Perceived Needs for and Use of Workplace Accommodations by Individuals With a Depressive and/or Anxiety Disorder. Journal of Occupational and Environmental Medicine, 2011, 53, 1268-1272.	1.7	42
547	Conceptualizing Excessive Behaviour Syndromes: A Systematic Review. Current Psychiatry Reviews, 2011, 7, 138-151.	0.9	32
548	A Quantitative Analysis of Suspected Environmental Causes of MS. Canadian Journal of Neurological Sciences, 2011, 38, 98-105.	0.5	46
549	Mortality Associated with Major Depression in a Canadian Community Cohort. Canadian Journal of Psychiatry, 2011, 56, 658-666.	1.9	18
550	The Pharmacoepidemiology of Antipsychotics for Adults with Schizophrenia in Canada, 2005 to 2009. Canadian Journal of Psychiatry, 2011, 56, 630-634.	1.9	9
551	Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, , .	0.6	16
552	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-598.	0.6	42
553	Distinct roles for <i>I</i> <sub>T</sub> and <i>I</i> <sub>H</sub> in controlling the frequency and timing of rebound spike responses. Journal of Physiology, 2011, 589, 5391-5413.	2.9	49
554	The association between antidepressant use and depression eight years later: A national cohort study. Journal of Psychiatric Research, 2011, 45, 1012-1018.	3.1	5
555	Clinical effectiveness, construct and assessment. Journal of Affective Disorders, 2011, 132, S3-S8.	4.1	3
556	Weight gain in relation to major depression and antidepressant medication use. Journal of Affective Disorders, 2011, 134, 288-293.	4.1	36
557	Associations between mammographic density and serum and dietary cholesterol. Breast Cancer Research and Treatment, 2011, 125, 181-189.	2.5	25
558	Operationalizing frailty among older residents of assisted living facilities. BMC Geriatrics, 2011, 11, 23.	2.7	40

#	Article	IF	CITATIONS
559	A Prospective Single-arm Open-label Study of Baclofen and Bupropion SR Combination Therapy for Smoking Cessation. Addictive Disorders and Their Treatment, 2011, 10, 101-104.	0.5	2
560	Major Depression Is a Risk Factor for Shorter Time to First Cigarette Irrespective of the Number of Cigarettes Smoked Per Day: Evidence From a National Population Health Survey. Nicotine and Tobacco Research, 2011, 13, 1059-1067.	2.6	22
561	The Pharmacoepidemiology of Antipsychotic Medications for Canadian Children and Adolescents: 2005–2009. Journal of Child and Adolescent Psychopharmacology, 2011, 21, 537-543.	1.3	79
562	Re: "Job Strain and the Risk of Depression: Is Reporting Biased?". American Journal of Epidemiology, 2011, 174, 125-125.	3.4	9
563	Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth. Paediatrics and Child Health, 2011, 16, 590-8.	0.6	16
564	Prevalence of Mental Disorders in a Canadian Household Population with Dementia. Canadian Journal of Neurological Sciences, 2010, 37, 186-194.	0.5	11
565	Workplace Characteristics, Depression, and Health-Related Presenteeism in a General Population Sample. Journal of Occupational and Environmental Medicine, 2010, 52, 836-842.	1.7	71
566	Pharmacoepidemiology of Benzodiazepine and Sedative-Hypnotic Use in a Canadian General Population Cohort during 12 Years of Follow-up. Canadian Journal of Psychiatry, 2010, 55, 792-799.	1.9	10
567	Predictors of the Longitudinal Course of Major Depression in a Canadian Population Sample. Canadian Journal of Psychiatry, 2010, 55, 669-676.	1.9	41
568	The Prevalence of Mental Disorders in the Working Population over the Period of Global Economic Crisis. Canadian Journal of Psychiatry, 2010, 55, 598-605.	1.9	76
569	Frequency of Antidepressant Use in Relation to Recent and Past Major Depressive Episodes. Canadian Journal of Psychiatry, 2010, 55, 532-535.	1.9	8
570	Major Depression and Injury Risk. Canadian Journal of Psychiatry, 2010, 55, 313-318.	1.9	33
571	Non-adherence with psychotropic medications in the general population. Social Psychiatry and Psychiatric Epidemiology, 2010, 45, 47-56.	3.1	101
572	Use of complementary and alternative medicine by those with a chronic disease and the general population - results of a national population based survey. BMC Complementary and Alternative Medicine, 2010, 10, 58.	3.7	134
573	Problems encountered with the use of simulation in an attempt to enhance interpretation of a secondary data source in epidemiologic mental health research. BMC Research Notes, 2010, 3, 231.	1.4	2
574	The incidence of major depression in Canada: The National Population Health Survey. Journal of Affective Disorders, 2010, 123, 158-163.	4.1	36
575	Simulation studies of age-specific lifetime major depression prevalence. BMC Psychiatry, 2010, 10, 85.	2.6	27
576	Health status and healthâ€related behaviors in epilepsy compared to other chronic conditionsâ€"A national populationâ€based study. Epilepsia, 2010, 51, 853-861.	5.1	94

#	Article	IF	CITATIONS
577	Regulation of neuronal activity by Cav3-Kv4 channel signaling complexes. Nature Neuroscience, 2010, 13, 333-337.	14.8	162
578	Challenges in screening for depression in multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 1406-1411.	3.0	29
579	Letter to the Editor: Context dependency of major depression. Psychological Medicine, 2010, 40, 1757-1758.	4.5	2
580	Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophrenia Research, 2010, 117, 75-82.	2.0	162
581	Reciprocal Effects of Social Support in Major Depression Epidemiology. Clinical Practice and Epidemiology in Mental Health, 2010, 6, 126-131.	1.2	35
582	Reciprocal Effects of Social Support in Major Depression Epidemiology. Clinical Practice and Epidemiology in Mental Health, 2010, 1, 126-131.	1.2	0
583	Patterns of benzodiazepine use in a Canadian population sample. Epidemiologia E Psichiatria Sociale, 2009, 18, 248-254.	0.9	20
584	Major Depression, Antidepressant Medication and the Risk of Obesity. Psychotherapy and Psychosomatics, 2009, 78, 182-186.	8.8	45
585	The effect of major depression on participation in preventive health care activities. BMC Public Health, 2009, 9, 87.	2.9	19
586	Major depression and health-related quality of life in Parkinson's disease. General Hospital Psychiatry, 2009, 31, 334-340.	2.4	16
587	A longitudinal community study of major depression and physical activity. General Hospital Psychiatry, 2009, 31, 571-575.	2.4	55
588	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S44-S53.	4.1	175
589	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S54-S64.	4.1	91
590	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults Journal of Affective Disorders, 2009, 117, S26-S43.	4.1	357
591	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. Journal of Affective Disorders, 2009, 117, S15-S25.	4.1	154
592	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. Journal of Affective Disorders, 2009, 117, S1-S2.	4.1	192
593	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. Journal of Affective Disorders, 2009, 117, S5-S14.	4.1	128
594	The relationship between major depression and marital disruption is bidirectional. Depression and Anxiety, 2009, 26, 1172-1177.	4.1	113

#	Article	IF	CITATIONS
595	Has †lifetime prevalence' reached the end of its life? An examination of the concept. International Journal of Methods in Psychiatric Research, 2009, 18, 221-228.	2.1	59
596	A population-based study on ways of dealing with daily stress: comparisons among individuals with mental disorders, with long-term general medical conditions and healthy people. Social Psychiatry and Psychiatric Epidemiology, 2009, 44, 666-674.	3.1	14
597	Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry, 2009, 9, 19.	2.6	77
598	Allergies and major depression: a longitudinal community study. BioPsychoSocial Medicine, 2009, 3, 3.	2.1	13
599	Designing a knowledge transfer and exchange strategy for the Alberta Depression Initiative: contributions of qualitative research with key stakeholders. International Journal of Mental Health Systems, 2009, 3, 11.	2.7	17
600	Longitudinal epidemiology of major depression as assessed by the Brief Patient Health Questionnaire (PHQ-9). Comprehensive Psychiatry, 2009, 50, 26-33.	3.1	54
601	Suicide. Lancet, The, 2009, 373, 1372-1381.	13.7	1,519
602	Prevalence of cardiovascular disease in people with diabetes with and without schizophrenia: a population-based cohort study. Canadian Journal of Diabetes, 2009, 33, 203.	0.8	0
603	Major Depression as a Risk Factor for High Blood Pressure: Epidemiologic Evidence From a National Longitudinal Study. Psychosomatic Medicine, 2009, 71, 273-279.	2.0	121
604	Population-Based Service Planning for Implementation of MBCT: Linking Epidemiologic Data to Practice. Psychiatric Services, 2009, 60, 1540-1542.	2.0	15
605	Disability Payments for Persons With Severe Mental Illness in Alberta, Canada. Psychiatric Services, 2009, 60, 686-688.	2.0	0
606	Cigarette Smoking, Stages of Change, and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 2009, 54, 204-208.	1.9	33
607	Re: The Bipolar Spectrum—A Bridge Too Far?. Canadian Journal of Psychiatry, 2009, 54, 348-349.	1.9	0
608	Prospective Evaluation of the Effect of Major Depression on Working Status in a Population Sample. Canadian Journal of Psychiatry, 2009, 54, 841-845.	1.9	20
609	Population-Based Service Planning for Implementation of MBCT: Linking Epidemiologic Data to Practice. Psychiatric Services, 2009, 60, .	2.0	5
610	Antidepressant Treatment for Major Depression in Multiple Sclerosis. International Journal of MS Care, 2009, 11, 174-179.	1.0	10
611	Disability Payments for Persons With Severe Mental Illness in Alberta, Canada. Psychiatric Services, 2009, 60, .	2.0	0
612	The relationship between body mass index and mental health. Social Psychiatry and Psychiatric Epidemiology, 2008, 43, 63-71.	3.1	61

#	Article	IF	CITATIONS
613	Non-remission of depression in the general population as assessed by the HAMD-7 scale. Depression and Anxiety, 2008, 25, 393-397.	4.1	3
614	Potentially inappropriate management of depressive symptoms among Ontario home care clients. International Journal of Geriatric Psychiatry, 2008, 23, 650-659.	2.7	17
615	Comorbidity of Migraine and Psychiatric Disorders—A National Populationâ€Based Study. Headache, 2008, 48, 501-516.	3.9	281
616	The happy docs study: a Canadian Association of Internes and Residents well-being survey examining resident physician health and satisfaction within and outside of residency training in Canada. BMC Research Notes, 2008, 1, 105.	1.4	59
617	Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. General Hospital Psychiatry, 2008, 30, 407-413.	2.4	207
618	Sensitization: The sine qua non of the depressive disorders?. Medical Hypotheses, 2008, 71, 872-875.	1.5	11
619	The prevalence and management of current daily pain among older home care clients $\hat{a}^{-}$ †. Pain, 2008, 138, 208-216.	4.2	97
620	Still no evidence that benzodiazepines cause depression. International Journal of Psychiatry in Clinical Practice, 2008, 12, 85-88.	2.4	2
621	Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 406-411.	3.0	24
622	Lifestyle Characteristics of Psychiatric Outpatients. Canadian Journal of Psychiatry, 2008, 53, 260-266.	1.9	42
623	The Bipolar Spectrum—A Bridge Too Far?. Canadian Journal of Psychiatry, 2008, 53, 762-768.	1.9	24
624	The Evolving Understanding of Major Depression Epidemiology: Implications for Practice and Policy. Canadian Journal of Psychiatry, 2008, 53, 689-695.	1.9	14
625	Major Depression Prevalence is Very High, but the Syndrome is a Poor Proxy for Community Populations' Clinical Treatment Needs. Canadian Journal of Psychiatry, 2008, 53, 411-419.	1.9	44
626	Confounding by severity and indication in observational studies of antidepressant effectiveness. Journal of Population Therapeutics and Clinical Pharmacology, 2008, 15, e367-71.	1.9	6
627	Mood and anxiety disorders, the association with presenteeism in employed members of a general population sample. Epidemiologia E Psichiatria Sociale, 2007, 16, 231-237.	0.9	26
628	Affective Disorders in Motor Neuron Disease: A Population-Based Study. Neuroepidemiology, 2007, 28, 1-7.	2.3	8
629	Incidence of Multiple Sclerosis among First Nations People in Alberta, Canada. Neuroepidemiology, 2007, 28, 21-27.	2.3	18
630	Firing Dynamics of Cerebellar Purkinje Cells. Journal of Neurophysiology, 2007, 98, 278-294.	1.8	83

#	Article	IF	CITATIONS
631	Frequency and Adequacy of Depression Treatment in a Canadian Population Sample. Canadian Journal of Psychiatry, 2007, 52, 780-789.	1.9	20
632	Self-Reported Allergies and Their Relationship to Several Axis I Disorders in a Community Sample. International Journal of Psychiatry in Medicine, 2007, 37, 11-22.	1.8	76
633	Disease Management for Depression in an Ms Clinic. International Journal of Psychiatry in Medicine, 2007, 37, 459-473.	1.8	19
634	Association of Mood, Anxiety, and Substance Use Disorders With Occupational Status and Disability in a Community Sample. Psychiatric Services, 2007, 58, 659-667.	2.0	27
635	Prevalence of Multiple Sclerosis in First Nations People of Alberta. Canadian Journal of Neurological Sciences, 2007, 34, 175-180.	0.5	26
636	Perceived Effectiveness of Mental Health Care Provided by Primary-Care Physicians and Mental Health Specialists. Psychosomatics, 2007, 48, 123-127.	2.5	19
637	Chronic Obstructive Lung Diseases and Prevalence of Mood, Anxiety, and Substance-Use Disorders in a Large Population Sample. Psychosomatics, 2007, 48, 496-501.	2.5	26
638	Climbing Fiber Discharge Regulates Cerebellar Functions by Controlling the Intrinsic Characteristics of Purkinje Cell Output. Journal of Neurophysiology, 2007, 97, 2590-2604.	1.8	62
639	Re: Effectiveness of Antidepressants. Canadian Journal of Psychiatry, 2007, 52, 750-750.	1.9	1
640	An animated depiction of major depression epidemiology. BMC Psychiatry, 2007, 7, 23.	2.6	17
641	Reasons for antidepressant prescriptions in Canada. Pharmacoepidemiology and Drug Safety, 2007, 16, 746-752.	1.9	47
642	Performance measures for evaluating services for people with a first episode of psychosis. Microbial Biotechnology, 2007, 1, 157-167.	1.7	11
643	Knowledge Transfer and Exchange: Review and Synthesis of the Literature. Milbank Quarterly, 2007, 85, 729-768.	4.4	708
644	Psychiatric Comorbidity in Epilepsy: A Populationâ€Based Analysis. Epilepsia, 2007, 48, 2336-2344.	5.1	859
645	Relapse rates in an early psychosis treatment service. Acta Psychiatrica Scandinavica, 2007, 115, 126-131.	4.5	21
646	Assessment of physical etiologies for mood and anxiety disorders in structured diagnostic interviews. Social Psychiatry and Psychiatric Epidemiology, 2007, 42, 462-466.	3.1	3
647	The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. Quality of Life Research, 2007, 16, 749-754.	3.1	38
648	Association of Mood, Anxiety, and Substance Use Disorders With Occupational Status and Disability in a Community Sample. Psychiatric Services, 2007, 58, 659-667.	2.0	5

#	Article	IF	CITATIONS
649	Fatigue in multiple sclerosis. , 2007, , 805-818.		2
650	Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults. Drugs and Aging, 2006, 23, 345-356.	2.7	75
651	Sedative Hypnotic Use in Alberta. Canadian Journal of Psychiatry, 2006, 51, 287-294.	1.9	20
652	Does Almost Everybody Suffer from a Bipolar Disorder?. Canadian Journal of Psychiatry, 2006, 51, 6-8.	1.9	31
653	Descriptive Epidemiology of Major Depression in Canada. Canadian Journal of Psychiatry, 2006, 51, 84-90.	1.9	297
654	Self-Reported Diagnoses of Schizophrenia and Psychotic Disorders May Be Valuable for Monitoring and Surveillance. Canadian Journal of Psychiatry, 2006, 51, 256-259.	1.9	30
655	Serum Monitoring of Antipsychotic Drug Levels during Concomitant Administration of Sertraline and Antipsychotic Medication. Canadian Journal of Psychiatry, 2006, 51, 715-718.	1.9	3
656	Forgetfulness: A Role in Noncompliance with Antidepressant Treatment. Canadian Journal of Psychiatry, 2006, 51, 719-722.	1.9	22
657	Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Population Health Metrics, 2006, 4, 15.	2.7	31
658	Epidemiological Associations between Gambling Behavior, Substance Use & Mood and Anxiety Disorders. Journal of Gambling Studies, 2006, 22, 275-287.	1.6	140
659	Self-reported thyroid disease and mental disorder prevalence in the general population. General Hospital Psychiatry, 2006, 28, 503-508.	2.4	28
660	Mental disorders in a population sample with musculoskeletal disorders. BMC Musculoskeletal Disorders, 2006, 7, 37.	1.9	75
661	Major depression, fibromyalgia and labour force participation: A population-based cross-sectional study. BMC Musculoskeletal Disorders, 2006, 7, 4.	1.9	64
662	Mental health and related disability among workers: A population-based study. American Journal of Industrial Medicine, 2006, 49, 514-522.	2.1	75
663	Psychiatric Side Effects of Interferon Treatment. Current Drug Safety, 2006, 1, 143-150.	0.6	25
664	A major depression prognosis calculator based on episode duration. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 13.	1.2	37
665	Prevalence of violence against women reported in a rural health region. Canadian Journal of Rural Medicine: the Official Journal of the Society of Rural Physicians of Canada = Journal Canadien De La Médecine Rurale: Le Journal Officiel De La Société De M&:#x00e9:decine Rurale Du Canada. 2006. 11. 259-67.	0.4	11
666	Assessment of mental health and illness by telephone survey: experience with an Alberta mental health survey. Chronic Diseases in Canada, 2006, 27, 99-109.	0.8	3

#	Article	IF	CITATIONS
667	Comorbidity of Major Depression and Migraine — A Canadian Population-Based Study. Canadian Journal of Psychiatry, 2005, 50, 832-837.	1.9	54
668	International Dosage Differences in Fluoxetine Clinical Trials. Canadian Journal of Psychiatry, 2005, 50, 31-38.	1.9	6
669	Psychotropic Medication Use in Canada. Canadian Journal of Psychiatry, 2005, 50, 605-613.	1.9	72
670	Antidepressant Pharmacoepidemiology in a General Population Sample. Journal of Clinical Psychopharmacology, 2005, 25, 285-587.	1.4	10
671	Descriptive Epidemiology of Affective Disorders in Multiple Sclerosis. CNS Spectrums, 2005, 10, 365-371.	1.2	24
672	Comorbidity of Major Depression with Substance Use Disorders. Canadian Journal of Psychiatry, 2005, 50, 660-666.	1.9	86
673	Long-Term Medical Conditions and Major Depression: Strength of Association for Specific Conditions in the General Population. Canadian Journal of Psychiatry, 2005, 50, 195-202.	1.9	137
674	Depression in multiple sclerosis. Acta Neurologica Scandinavica, 2005, 111, 209-209.	2.1	11
675	Clinical correlates of CES-D depressive symptom ratings in an MS population. General Hospital Psychiatry, 2005, 27, 439-445.	2.4	35
676	Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research. International Journal of Methods in Psychiatric Research, 2005, 14, 151-157.	2.1	7
677	Antidepressant utilization in Canada. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 799-807.	3.1	74
678	Drug treatment modalities in psychiatric inpatient practice. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 136-142.	3.2	10
679	Well-being in residency training: a survey examining resident physician satisfaction both within and outside of residency training and mental health in Alberta. BMC Medical Education, 2005, 5, 21.	2.4	160
680	Describing the longitudinal course of major depression using Markov models: Data integration across three national surveys. Population Health Metrics, 2005, 3, 11.	2.7	11
681	Help-Seeking Behaviours of Individuals with Mood Disorders. Canadian Journal of Psychiatry, 2005, 50, 652-659.	1.9	61
682	Markov models of major depression for linking psychiatric epidemiology to clinical practice. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 2.	1.2	17
683	Modelling major depression epidemiology and assessing the impact of antidepressants on population health. International Review of Psychiatry, 2005, 17, 205-211.	2.8	6
684	From the trenches: views from decision-makers on health services priority setting. Health Services Management Research, 2005, 18, 100-108.	1.7	17

#	Article	lF	CITATIONS
685	The association of depression with disease course in multiple sclerosis. Neurology, 2005, 64, 359-360.	1.1	63
686	Regional variation of multiple sclerosis prevalence in Canada. Multiple Sclerosis Journal, 2005, 11, 516-519.	3.0	122
687	A randomized, open″abel pilot comparison of gabapentin and bupropion SR for smoking cessation. Nicotine and Tobacco Research, 2005, 7, 809-813.	2.6	26
688	Canadian study finds that antidepressant use has increased in people with major depression over the past decade. Evidence-Based Mental Health, 2005, 8, 26-26.	4.5	0
689	Frontal Brain Asymmetry and Reward Responsiveness. Psychological Science, 2005, 16, 805-813.	3.3	281
690	The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 328-337.	3.0	290
691	The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 175-181.	3.0	72
692	Performance Measures for Early Psychosis Treatment Services. Psychiatric Services, 2005, 56, 1570-1582.	2.0	45
693	Interferon-α-Induced Depression: When a Randomized Trial Is Not a Randomized Controlled Trial. Psychotherapy and Psychosomatics, 2005, 74, 387-387.	8.8	9
694	Treatment of neuropsychiatric syndromes in multiple sclerosis. Expert Review of Neurotherapeutics, 2005, 5, 413-420.	2.8	4
695	Psychotic disorders in MS: Population-based evidence of an association. Neurology, 2005, 65, 1123-1125.	1.1	106
696	Predictive Value of the CES-D in Detecting Depression Among Candidates for Disease-Modifying Multiple Sclerosis Treatment. Psychosomatics, 2005, 46, 131-134.	2.5	93
697	An analysis of data from two general health surveys found that increased incidence and duration contributed to elevated prevalence of major depression in persons with chronic medical conditions. Journal of Clinical Epidemiology, 2005, 58, 184-189.	5.0	27
698	PMH39 THE USEFULNESS OF THE EQ-5D IN DIFFERENTIATING AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND ANXIETY. Value in Health, 2005, 8, 396.	0.3	0
699	Measurement issues related to the evaluation and monitoring of major depression prevalence in Canada. Chronic Diseases in Canada, 2005, 26, 100-6.	0.8	11
700	Major Depression and Mental Health Care Utilization in Canada: 1994 to 2000. Canadian Journal of Psychiatry, 2004, 49, 303-309.	1.9	57
701	Towards a dynamic description of major depression epidemiology. Epidemiologia E Psichiatria Sociale, 2004, 13, 21-28.	0.9	11
702	The effect of immunomodulatory treatment on multiple sclerosis fatigue. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1045-1047.	1.9	78

#	Article	IF	Citations
703	Refining Estimates of Major Depression Incidence and Episode Duration in Canada Using a Monte Carlo Markov Model. Medical Decision Making, 2004, 24, 351-358.	2.4	25
704	Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice. Acta Psychiatrica Scandinavica, 2004, 109, 275-278.	4.5	44
705	Epidemic theory and group violence. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 853-856.	3.1	32
706	The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Population Health Metrics, 2004, 2, 9.	2.7	17
707	Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Annals of Neurology, 2004, 55, 756-756.	5.3	156
708	Drug-Induced Depression: A Systematic Review to Inform Clinical Practice. Psychotherapy and Psychosomatics, 2004, 73, 207-215.	8.8	111
709	Adjustment to antidepressant utilization rates to account for depression in remission. Comprehensive Psychiatry, 2004, 45, 268-274.	3.1	14
710	International differences in major depression prevalence: what do they mean?. Journal of Clinical Epidemiology, 2004, 57, 762.	5.0	0
711	Epidemiological theory, decision theory and mental health services research. Social Psychiatry and Psychiatric Epidemiology, 2004, 39, 893-898.	3.1	9
712	The Changing Pattern of Inpatient Antipsychotic Drug Use in Italy. Journal of Clinical Psychopharmacology, 2004, 24, 559-561.	1.4	2
713	Recall bias and major depression lifetime prevalence. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 290-296.	3.1	108
714	Epidemiology of major depression in a predominantly rural health region. Social Psychiatry and Psychiatric Epidemiology, 2003, 38, 360-365.	3.1	27
715	Priority setting in health authorities: a novel approach to a historical activity. Social Science and Medicine, 2003, 57, 1653-1663.	3.8	68
716	Lifetime patterns of depressive symptoms in the community and among primary care attenders: an application of grade of membership analysis. Journal of Affective Disorders, 2003, 77, 31-39.	4.1	10
717	Irritable bowel syndrome: are incentives useful for improving survey response rates?. Journal of Clinical Epidemiology, 2003, 56, 256-261.	5.0	9
718	International differences in major depression prevalence: What do they mean?. Journal of Clinical Epidemiology, 2003, 56, 711-716.	5.0	34
719	Depressive symptoms in a treated multiple sclerosis cohort. Multiple Sclerosis Journal, 2003, 9, 616-620.	3.0	68
720	Major depression in multiple sclerosis. Neurology, 2003, 61, 1524-1527.	1.1	458

#	Article	IF	CITATIONS
721	Prevention of Depressive Symptoms Through the Use of Distance Technologies. Psychiatric Services, 2003, 54, 396-398.	2.0	57
722	Effect of Depression on Stroke Morbidity and Mortality. Canadian Journal of Psychiatry, 2003, 48, 250-257.	1.9	78
723	Mental Health Services Received by Depressed Persons Who Visited General Practitioners and Family Doctors. Psychiatric Services, 2003, 54, 878-883.	2.0	35
724	Irritable Bowel Syndrome and Health-Related Quality of Life: A Population-Based Study in Calgary, Alberta. Canadian Journal of Gastroenterology & Hepatology, 2003, 17, 259-263.	1.7	50
725	Dr. Fenton and Colleagues Reply. American Journal of Psychiatry, 2003, 160, 189-189.	7.2	3
726	Underuse of Antidepressants. American Journal of Psychiatry, 2003, 160, 189-a-190.	7.2	7
727	Major depressive episodes and diet pills. Expert Opinion on Pharmacotherapy, 2002, 3, 1405-1409.	1.8	2
728	Interferon $\hat{I}^21a$ and depression in secondary progressive MS: Data from the SPECTRIMS Trial. Neurology, 2002, 59, 744-746.	1.1	84
729	Major Depressive Disorder and Health Care Costs in Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2002, 32, 167-178.	1.8	10
730	Double-Blind, Placebo-Controlled Comparison of the Efficacy of Sertraline as Treatment for a Major Depressive Episode in Patients With Remitted Schizophrenia. Journal of Clinical Psychopharmacology, 2002, 22, 20-25.	1.4	54
731	Progress against Major Depression in Canada. Canadian Journal of Psychiatry, 2002, 47, 775-780.	1.9	25
732	The Association of Depressed Affect and Stroke in Institutionalized Canadians. Canadian Journal of Psychiatry, 2002, 47, 791-791.	1.9	0
733	Depression in Multiple Sclerosis Associated with Interferon Beta-1a (Rebif). Canadian Journal of Psychiatry, 2002, 47, 686-686.	1.9	25
734	Treatment-Seeking Rates and Associated Mediating Factors among Individuals with Depression. Canadian Journal of Psychiatry, 2002, 47, 660-665.	1.9	54
735	Major Depression and its Association with Long-Term Medical Conditions. Canadian Journal of Psychiatry, 2002, 47, 149-152.	1.9	50
736	Hopelessness Ratings in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2002, 32, 155-165.	1.8	22
737	The Moderating Effects of Coping Strategies on Major Depression in the General Population. Canadian Journal of Psychiatry, 2002, 47, 167-173.	1.9	33
738	Prospective study of frequent heavy alcohol use and the risk of major depression in the canadian general population. Depression and Anxiety, 2002, 15, 42-45.	4.1	61

#	Article	IF	Citations
739	Modeling methods for facilitating decisions in pharmaceutical policy and population therapeutics. Pharmacoepidemiology and Drug Safety, 2002, 11, 165-168.	1.9	7
740	A framework for describing the impact of antidepressant medications on population health status. Pharmacoepidemiology and Drug Safety, 2002, 11, 549-559.	1.9	18
741	Effects of a brief intervention on social support and psychiatric morbidity in breast cancer patients. Psycho-Oncology, 2002, 11, 282-294.	2.3	60
742	Medication use and major depressive syndrome in a community population. Comprehensive Psychiatry, 2001, 42, 124-131.	3.1	31
743	"Diet Pills―and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 2001, 46, 438-440.	1.9	4
744	Descriptive Epidemiology of a Depressive Syndrome in a Western Canadian Community Population. Canadian Journal of Public Health, 2001, 92, 392-395.	2.3	16
745	Using Databases to Prevent Inpatient Morbidity. Canadian Journal of Psychiatry, 2001, 46, 455-455.	1.9	1
746	A Prospective Study of Sex-Specific Effects of Major Depression on Alcohol Consumption. Canadian Journal of Psychiatry, 2001, 46, 422-425.	1.9	43
747	Perceived work stress and major depression in the Canadian employed population, 20–49 years old Journal of Occupational Health Psychology, 2001, 6, 283-289.	3.3	78
748	Alcohol Consumption and Major Depression: Findings from a Follow-up Study. Canadian Journal of Psychiatry, 2001, 46, 632-638.	1.9	51
749	Alternative Medicine Use by Individuals with Major Depression. Canadian Journal of Psychiatry, 2001, 46, 528-533.	1.9	31
750	Delirium in Psychiatric Inpatients: A Case-Control Study. Canadian Journal of Psychiatry, 2001, 46, 162-166.	1.9	23
751	Long-term medical conditions and major depression in a Canadian population study at waves $1$ and $2$ . Journal of Affective Disorders, 2001, 63, 35-41.	4.1	198
752	Perceived work stress and major depression in the Canadian employed population, 20-49 years old Journal of Occupational Health Psychology, 2001, 6, 283-289.	3.3	41
753	Interferon β-1a and depression in relapsing – remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Multiple Sclerosis Journal, 2001, 7, 243-248.	3.0	53
754	Major Depression and Quality of Life in Individuals with Multiple Sclerosis. International Journal of Psychiatry in Medicine, 2000, 30, 309-317.	1.8	90
755	The Predictive Value of Dysgraphia and Constructional Apraxia for Delirium in Psychiatric Inpatients. Canadian Journal of Psychiatry, 2000, 45, 75-78.	1.9	12
756	Major Depression Prevalence in Calgary. Canadian Journal of Psychiatry, 2000, 45, 923-926.	1.9	22

#	Article	IF	CITATIONS
757	Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis Journal, 2000, 6, 115-120.	3.0	160
758	Selection bias in studies of major depression using clinical subjects. Journal of Clinical Epidemiology, 2000, 53, 351-357.	5.0	31
759	The Utility of the Transtheoretical Model of Behavior Change for HIV Risk Reduction in Injection Drug Users. Journal of the Association of Nurses in AIDS Care, 2000, 11, 57-66.	1.0	14
760	The specificity of epidemiological correlates of major depression. Comprehensive Psychiatry, 2000, 41, 92-96.	3.1	2
761	Exogenous corticosteroids and major depression in the general population. Journal of Psychosomatic Research, 2000, 49, 447-449.	2.6	35
762	Corticosteroid-Induced Adverse Psychiatric Effects. Drug Safety, 2000, 22, 111-122.	3.2	152
763	Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Multiple Sclerosis Journal, 2000, 6, 115-120.	3.0	11
764	Democratizing the Institutions of Policy-making: Democratic Consultation and Participatory Administration. Journal of Canadian Studies, 2000, 35, 221-239.	0.9	27
765	Exogenous corticosteroid exposures are associated with increased recollection of traumatic life events. Journal of Affective Disorders, 1999, 53, 123-128.	4.1	2
766	Antihypertensive medications and depression, an historical perspective., 1999, 8, 355-359.		4
767	Depressive symptoms and disorders, levels of functioning and psychosocial stress: an integrative hypothesis. Medical Hypotheses, 1999, 53, 210-216.	1.5	14
768	Epidemics of violence. Medical Hypotheses, 1999, 53, 217-220.	1.5	9
769	Symptomatic therapies of multiple sclerosis. Biomedicine and Pharmacotherapy, 1999, 53, 371-379.	5.6	11
770	Long-Term Medical Conditions and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 1999, 44, 151-157.	1.9	88
771	The Reform Party's Re-imagining of the Canadian Nation. Journal of Canadian Studies, 1999, 34, 27-51.	0.9	10
772	Information needs and seeking behaviors of patients with inflammatory bowel disease. Gastroenterology, 1998, 114, A995.	1.3	5
773	Alcohol Consumption and Major Depression in the Canadian Population. Canadian Journal of Psychiatry, 1998, 43, 502-506.	1.9	32
774	Depression in people with first-episode schizophrenia. British Journal of Psychiatry, 1998, 172, 90-92.	2.8	282

#	Article	IF	CITATIONS
775	Drug-Induced Depression. Psychotherapy and Psychosomatics, 1997, 66, 63-73.	8.8	55
776	The Incidence of Delirium in Psychiatric Inpatient Units. Canadian Journal of Psychiatry, 1997, 42, 858-863.	1.9	16
777	Depression in Multiple Sclerosis. Psychotherapy and Psychosomatics, 1997, 66, 286-292.	8.8	89
778	Of Passionate Intensity: Right-Wing Populism and the Reform Party of Canada. Canadian Journal of Sociology, 1997, 22, 132.	0.2	0
779	Risk of suicide attempts after benzodiazepine and/or antidepressant use. Annals of Epidemiology, 1997, 7, 568-574.	1.9	68
780	Course, correlates and predictors of depression in schizophrenia. Schizophrenia Research, 1996, 18, 117.	2.0	0
781	H <sub>2</sub> Blocker Exposure as a Risk Factor for Depression. Canadian Journal of Psychiatry, 1996, 41, 537-538.	1.9	3
782	New Evidence on Benzodiazepine Use and Falls: The Time Factor. Age and Ageing, 1996, 25, 273-278.	1.6	142
783	Self-Reported Depressive Symptoms following Treatment with Corticosteroids and Sedative-Hypnotics. International Journal of Psychiatry in Medicine, 1996, 26, 15-24.	1.8	39
784	Caseâ€"Control Studies of Cardiovascular Medications as Risk Factors for Clinically Diagnosed Depressive Disorders in a Hospitalized Population. Canadian Journal of Psychiatry, 1996, 41, 469-476.	1.9	24
785	Depressive Symptoms Attributable to Medication Exposure in a Medical Inpatient Population. Canadian Journal of Psychiatry, 1996, 41, 651-654.	1.9	2
786	Gender and affect in schizophrenia. Canadian Journal of Psychiatry, 1996, 41, 265-8.	1.9	26
787	Organic Depression Associated with Flunarizine. Canadian Journal of Psychiatry, 1995, 40, 111-112.	1.9	13
788	Self-Reported Depressive Symptoms in Association with Medication Exposures among Medical Inpatients: A Cross-Sectional Study. Canadian Journal of Psychiatry, 1995, 40, 264-269.	1.9	10
789	A Case-Control Study of Corticosteroid Exposure as a Risk Factor for Clinically-Diagnosed Depressive Disorders in a Hospitalized Population. Canadian Journal of Psychiatry, 1995, 40, 396-400.	1.9	8
790	Drug-Induced Depression. Drug Safety, 1994, 10, 203-219.	3.2	18
791	Statistical Heterogeneity and Centre Effects in Clinical Trials of Alprazolam. Canadian Journal of Psychiatry, 1994, 39, 316-317.	1.9	0
792	Neuropsychiatric Adverse Drug Reactions: Passive Reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965-Present). International Journal of Psychiatry in Medicine, 1994, 24, 45-62.	1.8	19

#	Article	lF	CITATIONS
793	Clinical interpretation of the mini-mental state. General Hospital Psychiatry, 1993, 15, 254-259.	2.4	17
794	Delayed Sleep Phase Disorder after Traumatic Brain Injury. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, 31, 100-102.	0.5	63
795	Manic Symptoms Associated with the use of Captopril. Canadian Journal of Psychiatry, 1991, 36, 314-315.	1.9	7
796	Evaluation of the Modified Mini-Mental State Examination in a General Psychiatric Population. Canadian Journal of Psychiatry, 1991, 36, 507-511.	1.9	22
797	The Loss of a Parent during Childhood as a Risk Factor for Depression. Canadian Journal of Psychiatry, 1991, 36, 706-711.	1.9	22
798	Dr. Patten Replies. Canadian Journal of Psychiatry, 1990, 35, 457-457.	1.9	0
799	Propranolol and Depression: Evidence from the Antihypertensive Trials. Canadian Journal of Psychiatry, 1990, 35, 257-259.	1.9	36
800	Dysgraphia. Canadian Journal of Psychiatry, 1989, 34, 746-746.	1.9	4
801	Organic Mania Induced by Phenytoin: A Case Report*. Canadian Journal of Psychiatry, 1989, 34, 827-828.	1.9	12
802	Pharmacological Management of Refractory Depression. Canadian Journal of Psychiatry, 1989, 34, 451-456.	1.9	6
803	Posttraumatic Stress Disorder and the Treatment of Sexual Abuse. Social Work, 1989, 34, 197-203.	1.1	24
804	Sympatry and Interbreeding of Herring and Glaucous-Winged Gulls in Southeastern Alaska. Condor, 1974, 76, 343-344.	1.6	11